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ABSTRACT OF DISSERTATION 
MAST CELLS AS NOVEL EFFECTOR CELLS IN THE PATHOGENESIS OF 
CHRONIC GRAFT-VERSUS-HOST DISEASE 
 
Hematopoietic stem cell transplantation (HSCT) is most commonly a treatment for 
inborn defects of hematopoiesis or acute leukemias. Widespread use of HSCT, a potentially 
curative therapy, is hampered by onset of graft-versus-host-disease (GVHD), a condition 
wherein the donor cells recognize the patient tissues as non-self. GVHD can manifest 
anywhere from weeks to decades post-transplant and is classified as either acute or chronic 
GVHD, both of which are significant causes of transplant-related morbidity and mortality.  
However, GVHD is a complex, multifactorial, and enigmatic disease. The factors 
driving GVHD at the cellular and molecular level are incompletely understood. 
Immunosuppression targeting T-cells has not always been effective and increases the risk 
of relapse. Prophylactic immunosuppression can be particularly detrimental in the context 
of cGVHD, where symptoms can appear even decades after transplant. There is great need 
to further understand the mechanisms of GVHD pathogenesis in order to more effectively 
make use of HSCT.  
Mast cells are an arm of the immune system that are primarily known for their role 
in atopic disease. However, recent studies have demonstrated new paradigms for mast cell 
activity, showing that they can play important roles in tissue homeostasis and wound 
healing. Therefore, the purpose of this dissertation is to explore the role of mast cells in the 
onset of fibrotic chronic GVHD. We hypothesized that mast cells, through their 
interactions with tissue-resident and circulating GVHD effector cells, would be detrimental 
in chronic GVHD by exerting proinflammatory and profibrotic effects on the surrounding 
tissue. We examined mast cells in vitro in mono- and co-culture models, finding that they 
are significantly resistant to conditioning-induced cell death, as well as capable of inducing 
proliferation of fibroblasts. We further tested our hypothesis in vivo in murine models of 
allogeneic transplant using both wild type and mast cell-deficient mice. Compared to wild 
type recipients, mast cell-deficient recipients had significant reductions in GVHD 
symptomology and skin manifestations, as well as in chemokine levels and immune cell 
recruitment in the skin. We show that mast cell chemokine production is blocked by drugs 
currently used clinically to treat chronic GVHD, and that skin from GVHD patients is 
enriched in mast cells. Lastly, we show that recipient-derived mast cells are capable of 
surviving after transplant.  
Taken together, these data demonstrate a role for mast cells in the onset of dermal 
chronic GVHD. We therefore outline methods and pathways by which mast cells could be 
targeted for therapeutic inhibition and discuss future studies that would further clarify the 
function of mast cells in chronic GVHD pathogenesis. 
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CHAPTER 1. INTRODUCTION AND BACKGROUND 
1.1 Introduction 
 Hematopoietic stem cell transplantation (HSCT) is most commonly a treatment for 
inborn defects of hematopoiesis or acute leukemias. Widespread use of HSCT, a potentially 
curative therapy, is hampered by the development of graft-versus-host-disease (GVHD), a 
condition wherein the donor cells recognize the patient tissues as non-self, leading to  
dysregulated inflammation. GVHD can manifest anywhere from weeks to decades post-
transplant and is classified as either acute (aGVHD) or chronic GVHD (cGVHD), both of 
which are significant causes of transplant-related morbidity and mortality. Acute and 
chronic GVHD are complex, enigmatic diseases, displaying a variety of symptomology 
including facets that resemble autoimmune, chronic inflammatory, and atopic immune 
responses. 
 However, acute and chronic GVHD are complex, multifactorial, and enigmatic 
diseases. The factors driving either form of GVHD at the cellular and molecular level are 
incompletely understood. While alloreactive T-cells are often considered to drive much of 
acute GVHD symptomology, immunosuppression targeting T-cells has not always been 
effective and increases the risk of relapse. Prophylactic immunosuppression can be 
particularly detrimental in the context of cGVHD, where symptoms can appear even 
decades after transplant.  In chronic GVHD, both donor and recipient immune cells can 
participate in excessive and prolonged inflammation, causing organ damage. There is great 
need to further understand the mechanisms of GVHD pathogenesis in order to more 
effectively make use of HSCT. 
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 Mast cells are an arm of the immune system and are primarily known for their role 
in atopic disease. However, recent studies have demonstrated new paradigms for mast cell 
activity, showing that they can play important roles in tissue homeostasis and wound 
healing. In chronic graft-versus-host disease (cGVHD), aberrant wound healing 
mechanisms lead to pathological fibrosis across multiple organs, but the cellular etiology 
driving fibrosis is not well-understood. Even outside the context of GVHD, pathogenic 
fibrosis is incredibly common in the developed world, with up to 45 percent of all deaths 
associated with symptoms of chronic fibrosis1, making it a major public health concern and 
demonstrating the urgent need to better understand the mechanisms involved. 
 Therefore, the purpose of this dissertation is to explore the role of mast cells in the 
onset of fibrotic chronic GVHD. We hypothesized that mast cells, through their 
interactions with tissue-resident and circulating GVHD effector cells, would be detrimental 
in chronic GVHD by exerting proinflammatory and profibrotic effects on the surrounding 
tissue. In addition, we explored therapeutic options for inhibiting mast cell responses in 
cGVHD and investigated the survival and donor-versus-recipient origin of mast cells in the 
post-transplant environment.  
 
1.2 Skin – Structure and function 
The skin is the most commonly affected organ in cGVHD. It is also the largest 
organ in the body, with a weight of 8-10 pounds and surface area of 22 square feet in an 
average adult2. The skin is a physical barrier acting as the first line of defense against many 
infections or injuries. Since its surface is directly exposed to the environment, it is also 
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highly susceptible to environmental insults. Skin is also highly visible as an external 
marker of health, and disfiguring skin diseases or conditions often lead to social shaming 
or stigmas that can negatively affect an individual’s mental or physical health.  
These factors weigh heavily into the structure and function of the skin; its ultimate 
function is to maintain a homeostatic environment between the external world and the rest 
of the body3. As a barrier, it needs to restrict access to the rest of the body. As the most 
exterior organ, it needs to be able to signal its health and to regenerate when it is damaged. 
It needs to be able to summon a sufficient immune response to fight off infections that may 
be present.  
As we all learn when getting a scrape at a young age, skin is multi-layered. The 
outermost layer, or epidermis, consists of several layers of functionally differentiated cells. 
Most exterior is the stratum corneum, followed by the strata lucidum, granulosum, 
spinosum, and basale. The epidermis itself has no blood vessels, being reliant on diffused 
oxygen from the outside environment and from the underlying tissues. Each stratum is 
composed of cell bodies between one and twenty layers thick, depending on the stratum in 
question. Cells are formed at the basale layer and migrate outward, gradually changing 
function and producing additional keratin as they move. Because of this migration, capping 
the stratum corneum are several dozen layers of dead, highly keratinized cells that act as 
the outermost layer2. 
Underneath the epidermis is the dermis. The two are connected by a strong 
basement membrane, and the dermis contains hair follicles, sebaceous glands, lymphatic 
vessels, and many of the nerve endings in the skin. The dermis is vascularized, and 
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therefore also supplies nutrients to the lower layers of the epidermis. Collagen deposition 
by fibroblasts usually occurs here, and dermal thickening is a hallmark of many cutaneous 
fibrotic diseases4. Immune cells that enter the skin migrate from the lymphatic or blood 
vessels in the dermis, then transit to the appropriate location for their function.  
In addition to migratory cells, the skin contains tissue-resident cells such as 
Langerhans cells, macrophages, mast cells, and certain subsets of T-cells. These cells serve 
to patrol the local environment, looking for tissue damage or pathogens. Therefore, the 
tissue-resident immune cells act as sentinel cells engaged in maintaining a tissue integrity. 
This can consist of environmental sampling by Langerhans cells or wound healing, 
elimination of local infections, and recruitment of systemic immunity by macrophages and 
mast cells5.  
The dermis is also a site of fibrosis. Fibroblasts live in the dermis and are activated 
by local or systemic triggers, inducing myofibroblast differentiation, proliferation, and 
collagen deposition, often as a mechanism of wound healing and tissue repair. However, 
when this occurs in the context of chronic inflammation, dysregulation of these wound 
healing responses can occur, leading to dermal thickening by excessive collagen6.  
 
1.3 Hematopoietic stem cell transplantation 
Hematopoietic stem cell transplantation, or HSCT, is a procedure in which a patient 
undergoes conditioning to ablate or destroy their bone marrow, followed by introduction 
and engraftment of hematopoietic stem cells from a donor. This results in replacement of 
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the patient marrow with donor cells, creating a chimera wherein the hematopoietic system 
is derived from the donor, while the non-hematopoietic cells and tissues remain host 
derived. This is used as a treatment for a defective hematopoietic system, especially in the 
context of lymphoma, myeloma, or acute and some chronic leukemias. It can also be used 
for inborn defects of hematopoiesis such as aplastic anemia, sickle cell disease, or some 
metabolic disorders.  
1.3.1 Procedure 
The first step for any HSCT procedure is ensuring the patient is fit enough and 
willing to undergo transplant7. This must be a decision made between the patient and the 
care provider, all the while ensuring that there is an understanding of the patient’s 
underlying disease, comorbidities, chronic viral infection status, type of transplant, 
resources of the healthcare center and the home environment, and likely adherence to post-
transplant regimens. The patient, meanwhile, needs to come to recognize the risks and 
benefits associated with this treatment, and to be educated on transplant terminology that 
is very likely foreign to them. Patient age and functional status must be assessed by the 
physician; under certain conditions, elderly patients or those with poor organ function may 
be viably transplanted, or they may be candidates only for mild transplant regimens or 
alternatives to transplant. This decision is very multifactorial and patients are subject to an 
extensive pre-transplant workup and physical assessment8. 
Once the decision has been made to move ahead with transplant, either the patient’s 
own hematopoietic cells will be utilized (autologous transplant) or a suitable donor must 
be found. This is most often from an HLA-matched (related or unrelated) allogeneic donor, 
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and less frequently from a mismatched unrelated donor, from a parent or child (a 
haploidentical transplant) or using cord blood. The HLA system, coding for the major 
histocompatibility complex (MHC) in humans, is generally responsible for self vs. non-
self differentiation via positive and negative selection of the developing T-cell repertoire 
in the thymus.  THe HLA system is also critical to identify a potential hempatoietic stem 
cell donor. Donor matching is based on the HLA genes, consisting of HLA-A, -B, -C, 
DRB1, DQB1 and increasingly DP9. The level of genetic and phenotypic diversity can 
make it difficult to find a fully patient-matched donor for allogeneic transplants. Donor 
matching is based on the type of transplant recommended by the patient’s care team as well 
as the timeline in which a transplant is needed10. Matching a patient with a donor is usually 
performed through public registries such as “Be The Match”, which is operated by the 
National Marrow Donor Program.  
Donor stem cell source can be another complex decision. In the past, whole bone 
marrow extracted from the iliac crest of the donor was used. Much more commonly today, 
the donor is treated with granulocyte colony stimulating factor (G-CSF), which mobilizes 
stem cells from the marrow into the peripheral blood. These stem cells are then collected 
and concentrated by apheresis, and this product is used for infusion. Umbilical cord blood 
can also be a source of stem cells, though this is not always an option. The stem cell source 
has been shown to sometimes lead to differences in overall transplant outcome.  
After a donor has been identified that will be suitable for the current indication, 
risks and benefits have been assessed and reviewed with the patient the patient will then 
undergo pre-transplant conditioning. This is usually separated into myeloablative (MA), 
reduced-intensity conditioning (RIC), or nonmyeloablative (NMA) conditioning. 
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Conditioning is performed with either alkylating agents, total body irradiation (TBI), or a 
combination of the two;  RIC regimens usually reduce the dosage by 30 percent or more. 
Historically, high-dose conditioning was the standard of care, but in recent years RIC-
based and NMA regimens have become more common, allowing physicians to offer 
allogeneic HCT to older and frailer patients as well. Commonly used chemotherapeutic  
agents include busulfan, cyclophosphamide, fludarabine, AraC, and melphalan, among 
others. TBI is used most often as a fractionated dose, with a final exposure of 12-16 Gy for 
high-dose conditioning, or 2-6 Gy for RIC and NMA11.   
Post-conditioning, patients are infused with the donor stem cells.  Blood counts are 
monitored daily for engraftment (as measured by neutrophil and platelet counts in 
peripheral blood). Once the clinical team is sure of engraftment, the patient can most often 
be safely discharged and monitored as an outpatient7.  
 
1.3.2 HSCT Subtypes 
HSCT has two main subtypes: autologous and allogeneic. In an autologous 
transplant, hematopoietic stem cells are extracted from the patient and cryopreserved, then 
after conditioning, the extracted bone marrow is re-engrafted into the patient. A rarer type 
of transplant, syngeneic HSCT, uses bone marrow donated from an identical twin, and is 
rarely used clinically, but is used extensively in murine models due to genetic matching 
between littermates12. In both autologous and syngeneic transplants, there is no self-
reactivity and little-to-no GVHD since the cells are derived from a genetically identical 
source. Autologous transplants still carry risk, though better conditioning regimens and 
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post-transplant care have allowed for the use of autologous transplants even in an outpatient 
setting13.  
In contrast, allogeneic transplants (allo-HSCT), comprising greater than 40 percent 
of all HSCT procedures, are transplants from a related or unrelated HLA-compatible donor 
(either fully or partially HLA-matched, haploidentical, or cord blood)14. These transplants 
run the risk of graft-versus-host disease, but also greatly reduce relapse rates through post-
transplant immunosurveillance by donor cells. Fully or partially HLA-matched transplants 
are most common, although haploidentical transplants are recently becoming an option for 
more patients. In large part this is due to the use of post-transplant cyclophosphamide, 
which helps to prevent alloreactive clones from expanding15,16. 
 
1.3.3 Indications 
Most HSCTs are performed as a treatment for hematologic malignancy. 
Autologous transplants are used most commonly for lymphomas and multiple myeloma13.  
Allogeneic transplants often present the only chance of cure17, yet sometimes are 
seen as a double-edged sword. More than 24,000 allogeneic HSCTs are carried out 
annually. 72% of all allo-HSCTs are performed on patients with leukemia, with AML alone 
accounting for more than half of all allogeneic transplants. Allogeneic HSCT can also be 
performed for treatment of inborn defects of hematopoiesis or some metabolic disorders. 
For patients with diseases such as severe aplastic anemia, thalassemia, or peroxisomal 
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storage disorders, allogeneic HSCT can offer hope of a cure; the donor blood-forming 
system would ideally completely supplant the defective host system18,19.  
Especially in older patients, HSCT is often overlooked as first-line therapy in many 
diseases, although it is being increasingly considered with RIC regimens and haploidentical 
transplants offering additional options for patients and healthcare providers11. In AML, 
where the patient population is elderly and often impacted with severe disease, many 
treatment strategies are viewed as a “bridge to transplant,” where the goal is to get the 
disease burden under control while keeping the patient sufficiently healthy to undergo 
allogeneic HSCT20. The recent glut of FDA approved treatments for AML allows doctors 
more choice as to how to bridge a patient to transplant most effectively21. 
 
1.3.4 Donor vs. recipient paradigm 
Of great importance in the discussion of HSCT and GVHD is the paradigm of donor 
(or “graft-derived”) versus recipient (or “host-derived”) cells. The idea behind the 
conditioning phase prior to HSCT is to greatly reduce or entirely eliminate immune cells 
and bone marrow from the recipient. This allows for engraftment of the donor stem cells 
to the marrow, where they take up the burden of hematopoiesis. However, the cells in the 
organs, tissues, etc., are non-hematopoietic in origin and do not derive from the bone 
marrow. 
Therefore, after a successful allogeneic HSCT, a patient will be a chimera wherein 
the immune and blood-forming system has reconstituted from the donor stem cells, while 
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the non-hematopoietic cells will be derived from the host.  Some host-derived immune 
cells, especially some tissue-resident cells and APCs, are considered to survive the 
conditioning phase. As will be discussed later in this dissertation, we also have strong 
evidence supporting mast cell survival after conditioning as well. These recipient-derived 
cells often play a key role in initiation of GVHD through their cross-talk with donor-
derived cells.  
 
1.3.5 Elimination of residual host-derived cells and graft-versus-leukemia 
One manifestation of graft-versus-host reactivity is alloreactive elimination of host-
derived cells22. After HSCT, many of the immune cells coming out of the marrow go 
through some degree of positive and negative selection, a process that minimizes 
alloreactivity. However, in GVHD this process can often go awry, with thymic dysfunction 
leading to defective negative selection of T-cells, allowing for alloreactive clones to exit 
the thymus23. Additionally, alloreactive B-cells can be stimulated by IL-4, IL-13, and IL-
21 produced by both host and donor cells, which stimulates germinal center formation and 
antibody production24. This can lead to the donor immune system developing reactivity 
against self-antigens expressed on host cells. 
While GVHD primarily targets tissues, residual immune cells can also be 
eliminatedby donor-derived T-cells. Alternatively, autoantibodies can target host cells and 
tissues, which can trigger their elimination by various methods, depending on the isotype 
of antibody being produced. Donor-derived NK cells, while substantial effectors of the 
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GVL effect, can also target residual cells based on the degree of mismatch in MHC class I 
between the donor and host25.  
Alloreactive elimination of recipient  cells has been proven to be beneficial when 
it relates to residual or recurrent cancer cells.  Even in the context of a fully MHC-matched 
transplant, minor histocompatibility antigen mismatches and cancer related antigens can 
be expressed to the donor immune system. This effect is known as the graft-versus-
leukemia (GVL) effect22,26. By recognizing and eliminating residual leukemic cells that 
have survived conditioning, the donor immune cells can significantly lower relapse rates 
by clearance of latent disease post-conditioning. This is one of the main understood 
therapeutic mechanisms of action of allogeneic HSCT. Conditioning can be effective at 
removing residual cancerous cells, but these residual cancer cells can also be prime target 
for alloreactive elimination by the donor immune system. It is therefore unsurprising that 
the degree of GVHD is often inversely correlated with relapse rates; a patient who develops 
severe GVHD will likely have sufficient alloreactivity to kill the residual cancer cells.  
Considering the potentially detrimental character of GVHD compared to the beneficial 
effects of GVL , separating GVHD from GVL is one of the main goals of research in this 
field.  
 
1.4 Graft-versus-host disease 
Graft-versus-host disease (GVHD) is the single biggest limiting factor of the 
widespread use of HSCT. While infections, veno-occlusive disease, and mucositis can also 
cause patient morbidity and mortality, they are either not as common or not as severe 
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outside the context of GVHD. Therefore, prevention of GVHD is one of the main goals of 
the transplant field, as deaths due to GVHD account for 20 percent or more of the mortality 
after transplant27. Moreover, quality-of-life can be significantly affected in both acute and 
chronic GVHD. 
GVHD can potentially affect any organ system and occurs in roughly 50 percent of 
patients post-transplant. Severity of GVHD can be mild to severe; gut GVHD is both 
common and potentially deadly in an acute setting, while skin and lung chronic GVHD are, 
respectively, the most common and most deadly forms of chronic GVHD.  
 
1.4.1 Acute graft-versus-host disease 
Acute GVHD is often induced by conditioning-related tissue damage, wherein 
damaged tissue releases danger signals which activate host-derived APCs, which can cause 
T-cell activation and proliferation These danger signals often include TNF-alpha, IL-1 
beta, and lipopolysaccharide, with the latter occurring by release of endogenous bacteria 
into systemic circulation. The signals themselves and the responding cells that they activate 
contribute to a phenotype known as a “cytokine storm,” wherein massive levels of 
inflammatory cytokines are released28. This cytokine storm can cause organ failure and 
lead to patient mortality by itself or in combination with other factors. Historically, aGVHD 
was classified as any GVHD that occurs less than 100 days post-transplant, but this 
definition has largely been superseded by clinical presentation of disease and the 
recognition of late acute GVHD29. Late aGVHD can manifest more than 100 days after 
transplant but still display the characteristic signs and symptoms of aGVHD. 
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As has been mentioned, host-derived dendritic cells (DCs) are key drivers in early 
allogeneic T-cell responses. In addition, donor-derived DCs, once they are produced from 
the marrow, can amplify alloreactivity from T-cells and associated inflammatory cytokine 
production.  . These responses often include massive cytokine production either directly 
from T-cells or from cells activated by the T-cell response, especially type I cytokines such 
as IL-1beta, TGF-beta, TNF-alpha, IL-2, and IFN-gamma30.  
In the case of an MHC-mismatched transplant, direct mismatching can lead to 
immunodominant T-cell clones and progressive aGVHD. However, high levels of HLA 
mismatch are increasingly rare in the clinical setting, and alloreactive T-cells often 
establish immunodominant clones that recognize minor histocompatibility antigens31. 
Presence of these clones can be predictive of GVHD onset, and sometimes the course and 
severity of the disease.  
Acute GVHD is graded as Stage I-IV for each organ, with IV being the most severe. 
Primary organs involved are skin, liver, and upper and lower GI tract. Skin is the most 
common, and liver is least common. Upper GI disease presents in 24-60 percent of patients 
but is likely underreported due to the difficulty of biopsy. Lower GI tract GVHD has the 
highest risk of non-relapse mortality for patients after transplant. Biopsies of affected 
organs are often taken to confirm an initial diagnosis of aGVHD and to rule out other 
diagnoses29. 
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1.4.2 Chronic graft-versus-host disease 
Chronic GVHD  is a late complication that occurs in about 50 percent of patients 
that have undergone hematopoietic stem cell transplant. In contrast to acute GVHD, which 
is characterized by acute inflammation, massive cytokine production, and barrier 
dysfunction, chronic GVHD appears much more autoimmune in its mechanisms of 
pathogenesis. It is complex and poorly understood but is known to involve crosstalk and 
interactions between T-cells, B-cells, neutrophils, and tissue resident cells. One of the 
primary characteristics of cGVHD is inappropriate collagen deposition induced by an 
aberrant wound-healing mechanism23. Post-conditioning, tissue-resident cells attempt to 
regulate the initial cytokine storm of acute GVHD through production of anti-inflammatory 
cytokines and fibrogenetic factors to repair tissue damage23. This production of anti-
inflammatory mediators, while initially helpful in controlling alloreactive immune 
responses, leads to inappropriate collagen deposition and fibrotic disease.  
cGVHD can affect any organ system, with key symptoms often related to increased 
collagen deposition. Histologically, these changes are often seen to be relatively acellular, 
although this can change depending on the disease presentation. This fibrotic phenotype is 
an irreversible, end stage disease, and while symptom management has improved, overall 
incidence has not decreased. For instance, lung involvement of cGVHD has been 
underestimated for decades32. Both restrictive and obstructive lung function changes are 
found, and bronchiolitis obliterans syndrome (BOS) is now understood as a classical form 
of cGVHD of the lung. It is one of the only pathognomonic symptoms of cGVHD and is 
associated with particularly poor prognosis due to these irreversible structural changes in 
the architecture of the lung.  
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While aGVHD is a risk factor for later onset of cGVHD, the two can occur 
independently. Therefore, it is possible for a patient to develop aGVHD, recover, and never 
develop cGVHD. Alternately, a patient can develop de novo cGVHD without ever having 
developed aGVHD. Late cGVHD can even develop years or decades post-transplant; a 
patient who has previously shown no signs of GVHD can be subject to some initiating 
insult leading to onset of the disease. Our understanding of what events begin this process 
is severely limited and can severely limit a patient’s return to normal life and everyday 
behaviors after transplant.  
Ultimately, cGVHD is a disease whose treatment is hampered by an incomplete 
picture of the events that initiate and maintain its progression. Certain patient populations 
and characteristics, underlying diseases, aGVHD status, conditioning regimens, viral 
seropositivity status, and many other factors contribute to whether a given patient develops 
cGVHD and the type of disease that manifests28,33. Therefore, it is best to approach 
treatment of cGVHD mechanistically; targeting of pathways involved will likely have a 
better outcome than attempting to control each factor pre-transplant. This is an approach 
that has thus far borne fruit.  The finding that germinal center B-cells were involved in 
cGVHD pathogenesis in multiple organ systems led to the preclinical use of ibrutinib, a 
BTK inhibitor34.  
Cytokines and chemokines are important in cGVHD. In a study of nearly 300 
patients with cGVHD, the CXCR3 ligand CXCL10 was identified as the only consistent 
serum biomarkers of the disease in both of the cohorts that were analyzed35. At the same 
time, a combination of biomarkers including CXCL10 and BAFF seemed to have better 
prognostic value than either alone, although this work is still ongoing and being replicated 
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in multicenter studies. At the tissue level, dysregulated TGF-beta signaling seems to be 
very important in establishment of pathogenic fibrosis36. TLR pathway activation can drive 
production of IFN-gamma, IL-6, and IL-1 beta, which together can promote Th17 
differentiation and pathogenic IL-17 production37–39. IL-33 production by damaged tissue 
can also further activate fibroblasts and immune cells, mast cells included40. Together, 
these factors drive a positive feedback loop of chronic inflammation alongside aberrant 
wound-healing responses, which can drive fibrotic disease.  
Targeting specific pathways in cGVHD also has benefit for minimalization of the 
GVH response. Our work with mast cells takes this approach; we demonstrate that tissue-
resident mast cells that are critical in initiation of cGVHD41. Specific inhibition of these 
cells may therefore allow for GVL without GVHD. Overall, control and prevention of 
cGVHD will not be possible until further research is completed that allows a deeper 
knowledge of pathways involved, which will hopefully allow for immune and cGVHD 
suppression while retaining the potentially curative GVL effect.  
 
1.4.2.1 Dermal involvement in chronic graft-versus-host 
disease 
In chronic GVHD, the most frequently involved organ is the skin, with symptoms 
often presenting as sclerosis alongside increased collagen deposition42,43. Scleroderma-like 
cGVHD observed in transplant survivors can result in skin thickening and stiffness at 
localized sites or can manifest over extended areas of the body which can lead to full loss 
of mobility and entire body encasement. Other cutaneous manifestations of cGVHD 
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include lichen planus-like disease, morphea-like features, depigmentation, erythema, and 
ulceration4,44. In addition to the social stigma of widespread skin disease, these 
manifestations can have a significant negative impact on patient quality of life.  
Histologically, sclerotic dermal cGVHD presents as a thickening of the dermis due 
to massively increased collagen deposition. This collagen layer is relatively acellular, 
though fibroblasts are still present alongside scattered infiltrating cells44. Skin 
manifestations of cGVHD occur in 70% of patients, with sclerotic disease presenting in 
15-40% of cGVHD patients42,45,46. 
 
1.4.3 Murine models 
In humans GVHD can manifest in many different organ systems and display an 
incredibly wide range of clinical symptomology. For decades, researchers have used 
murine models of bone marrow transplant as a surrogate for human disease. These models 
are performed by transplanting bone marrow and/or splenocytes harvested from a donor 
mouse into a recipient mouse that has undergone conditioning. This conditioning, as in 
patients undergoing HSCT, is most often based on chemotherapy or total body 
irradiation47.  
Used as a negative controls that should not show the disease phenotype, syngeneic 
transplants are readily achievable in murine models by using genetically identical mice of 
the same strain. Allogeneic transplants are often used to model graft-versus-host disease, 
the severity, penetrance, and organ-specific manifestations of which depend on the degree 
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of MHC-matching between the donor and recipient, the T cell dose, and the conditioning 
intensity. Murine allogeneic transplants, while they do not individually capture the entire 
clinical spectrum seen in human disease, allow for a more focused analysis of specific 
aspects of GVHD. As with GVHD itself, these models are broadly subtyped into those that 
induce acute or chronic disease, and GVHD phenotype is to some extent strain dependent.  
Generally, a full MHC-mismatched transplant (such as the widely used BALB/C 
[H2b]  C57BL/6 [H2d] model) displays characteristics of acute GVHD, with severe 
wasting, gut dysfunction, massive inflammation, and death occurring in most animals 
within 14 days48. Most often, a lethal dose of total body irradiation is used to condition the 
recipient mice, the radiation source, fractionation, and duration of which can change the 
characteristics and severity of the cytokine storm phase of aGVHD. To better correlate 
murine models with a clinical transplant setting where MHC mismatching is rare, mouse 
models of aGVHD have been developed that rely entirely on minor histocompatibility 
mismatches. These models, including the DBA/2  B10.D2 (H2d  H2d)49 and C3H.SW 
 C57BL/6 (H2b  H2b)50, develop lethal aGVHD although the phenotype of the disease 
can differ between models. 
Mouse models of cGVHD attempt to recapitulate the smoldering inflammation, 
thymic dysfunction leading to dysfunctional Treg cells, and pathogenic fibrosis often seen 
in patients51. Sclerodermatous disease is most common in the skin, and two miMHC-
mismatched mouse models of transplant (TBI conditioning followed by B10.D2  
BALB/C52 or LP/J  C57BL/653) display extensive scleroderma and limited mortality, 
with fibrosis and dermal thickening evident from day 30 onward. Autoantibody deposition 
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leading to lupus-like symptoms are also characteristic of cGVHD and can be modeled with 
the DBA2  B6D2F1 model, which results in splenomegaly due to B-cell expansion.  
Depending on the dose of conditioning, cytokine milieu, donor marrow, or donor 
splenocytes, some models using the same level of MHC mismatch can be shifted to display 
symptoms of aGVHD or cGVHD. For instance, the DBA2  B6D2F1 model of 
autoantibody-mediated cGVHD can be skewed towards aGVHD through the addition of 
IL-12, a classical Th1 cytokine54. Further, the LP/J C57BL/6 model, when used with 
excess splenocytes or a higher radiation dose, develops fulminant and lethal aGVHD34.  
Measurement of murine GVHD severity is assessed by scoring systems that 
monitor the overall health and liveliness of the animal. Cooke et al. published on a system 
that is used in our lab and has been extensively adopted by the field55. Mice are scored for 
GVHD by assessment of five clinical parameters: weight loss, posture (hunching), activity, 
fur texture, and skin integrity. Individual mice receive a score of 0 to 2 for each criterion 
(maximum score of 10) that is used as an index of severity and progression of disease. 
Scoring systems such as these allow for animal experiments to be performed humanely in 
addition to giving each lab a measurement that can be used to track transplant outcome.  
 
1.5 Immune involvement in graft-versus-host disease 
Immune cells are the main driver in the symptoms of GVHD. Although there is still 
much debate as to the relative contributions of each cell type, T-cells are considered to be 
the canonical effector cell in GVHD, with CD4 and CD8 T-cells each involved in the onset 
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of the disease. In addition, macrophages, B-cells, neutrophils, and as the subject of this 
dissertation, mast cells, have all been shown to play a role in the onset or maintenance of 
GVHD.  
 
1.5.1 Adaptive immunity 
GVHD has traditionally been defined as a disease driven by alloreactive donor-
derived CD4 and CD8 T-cells responding to non-self antigens presented by host-derived 
antigen-presenting cells (APCs) and target tissues30. While this is certainly true in aGVHD, 
in recent years, studies have shown a heavy level of B-cell involvement in cGVHD as well, 
particularly germinal center B-cells through their IL-21 mediated interactions with T-
follicular helper cells24. While relative contributions are difficult to deconvolute, it is 
abundantly clear that adaptive immunity is a major driver of pathogenesis in both acute 
and chronic GVHD.  
The cytokine storm phenotype that can often occur in the early phases of aGVHD 
potentiates host-derived APCs to activate donor-derived T-cells. This occurs through 
presentation of self-antigens, which induces alloreactive donor T-cell activation and 
proliferation, followed by their trafficking to the tissues and causing many of the 
pathologies associated with GVHD.  
Th1, Th2, and Th17 cells have all been shown to play a role in pathogenesis of 
GVHD. In aGVHD, proinflammatory Th1 cells are the primary T-cells involved, while in 
cGVHD, Th2 and Th17 cells have both been shown to play a role. This takes place 
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especially through production of IL-17A, IL-4, and IL-13, which can promote fibrosis and 
production of alloreactive antibodies. In aGVHD, a unique subset (non Th1, Th2, Th17) of 
granzyme A-producing Th cells has also been shown to further disease progression through 
a STAT3-dependent mechanism56.  
Tfh cells seem to be more directly involved in fibrotic manifestations of GVHD. 
ICOS+, IL-21-producing Tfh cells are known to contribute to skin fibrosis in other models 
of scleroderma57, and this appears to be the case in cGVHD as well. Flynn et al. showed 
that Tfh cells produce IL-21 in cGVHD, which promotes germinal center formation and 
autoantibody production from GC B-cells, thereby increasing disease burden. Inhibition of 
this process through IL-21 blockade reversed this finding24.  
In contrast to other T-cells Tregs are a cell type involved in tissue homeostasis and 
downregulation of inflammation. Almost universally in sites of GVHD-mediated tissue 
damage, there is a significant increase in the T-effector:Treg ratio. Homeostatic control of 
GVHD can be maintained in settings that promote Treg survival and proliferation or after 
exogenous addition of Tregs. Given the differences in the tissue environment between 
acute and chronic GVHD, it is perhaps surprising that Tregs seem to be critical for 
reduction of disease in both settings27. 
B-cells are also implicated in GVHD pathogenesis. For acute GVHD, the evidence 
of B-cell involvement is not as strong as for chronic GVHD; recipient B-cells are thought 
to be eventually eliminated after HSCT and donor B cells are not as significant of a 
proportion of the graft as T-cells. In combination with the evidence that GC B-cells may 
be drivers of pathogenesis in cGVHD, it seems that these are donor-derived B-cells that 
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may not be numerous or mature enough to play a major role in early aGVHD. As a proof 
of concept, a drug targeting BTK, is the only FDA-approved drug for chronic GVHD and 
has been shown to reduce GVHD and enhance GVL in murine models34. In cGVHD, BAFF 
signaling is found to be hugely important for B-cell pathogenesis, with long-term 
overexpression of BAFF levels alongside antigenic signaling driving B-cell proliferation 
and antibody production58. 
Of course, as GVHD is such a heterogenous disease, different aspects of adaptive 
immunity can be at play in local sites within the same patient. This makes biomarker studies 
particularly difficult. For instance, liver and skin fibrosis can both occur in cGVHD, but 
seem to do so by different mechanisms, with Tfh cells being more important for 
scleroderma, and Th17 cells being critical for development of liver fibrosis59. 
1.5.2 Innate immunity 
While the adaptive immune system is critically important in GVHD, there is an 
increasing body of research showing that innate immunity also plays a large role on its own 
as well as in initiating and amplifying adaptive immune responses. Induction and 
maintenance of innate immune responses through cytokines including canonical pro-
inflammatory factors such as IFN-γ, TNF-α, IL-1, and IL-6, as well as more mercurial 
cytokines including TGF-β, IL-10, and IL-17, have all been demonstrated in recent years. 
In addition to establishing this proinflammatory environment through cytokine production, 
innate APCs such as dendritic cells or macrophages are critical to activating donor-derived 
T-cells. 
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The innate response is thought to be initiated through loss of intrinsic barriers or 
transient tissue damage, leading to bacterial infiltration and the release of pathogen-
associated-molecular-patterns (PAMPs) and damage-associate-molecular-patterns 
(DAMPs)60. Innate cells generally express very high level of DAMP and PAMP receptors 
and are exquisitely sensitive to stimulation by these classes of molecules. Tissue damage 
and loss of physical barriers leads to further stimulation and cytokine production by tissue-
resident cells, which then exacerbate the initial insult through the establishment of a 
feedback loop of chronic inflammation characteristic of GVHD.  
One of the critical steps in acute GVHD is presentation of self-antigen by recipient 
APCs to alloreactive donor T-cells. For example, in the gut, conditioning causes a 
breakdown in the epithelial barrier, leading to IL-33 release from damaged cells, LPS and 
other PAMPs from gut commensal bacteria that cross the damaged barrier, and DAMPs 
such as extracellular DNA or ATP, uric acid, and HMGB161. These bind to ST2, TLR4, or 
other receptors on the cell surface. The receptor repertoire expressed by an individual cell 
can drive its response in different directions. Exemplary of this is ATP, which binds to 
P2X7 on mast cells and induces degranulation, but binds to P2Y2 on macrophages and 
stimulates IL-1b production62. For dendritic cells, this multitude of signals is often 
integrated by coming together through activation of a central transcription factor such as 
NF-kB or AP1. This integrated signal helps to drive the DC to maturation and enhances its 
antigen presentation and T-cell stimulatory capacity, allowing for the detrimental 
alloreactive responses seen in gut GVHD60.  
Neutrophils and macrophages are often among the first cells to respond to an injury 
or insult. These cells are activated by the tissue damage and commensal infiltration, 
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producing reactive oxygen species (ROS) in an attempt to sterilize the area. This ROS 
production can lead to tissue damage and enhancement of GVHD; patients with defective 
ROS production, as in chronic granulomatous disease, have significantly reduced rates of 
GVHD after transplant. In both acute and chronic GVHD, tissue damage mediated by these 
granulocytes (among others such as eosinophils, whose absence in the tissues is a 
biomarker of improved clinical outcome63) is very common48.  
The concept of mast cells as initiators of fibrosis has come to prominence in recent 
years, but until our work, it had not been studied in the context of chronic GVHD. 
Preliminary research on this topic was performed several decades ago although it has not 
since been thoroughly investigated, likely because of the lack of effective models of mast 
cell deficiency and the need for better murine models of cGVHD64,65. The development of 
mast cell-deficient mice and refinement of the murine models of allo-HSCT has now 
allowed for a more thorough investigation into the role of mast cells in cGVHD 
pathophysiology. Previous work by Leveson-Gower et al. has shown that the presence of 
mast cells is beneficial in the context of acute GVHD through mast cell production of anti-
inflammatory factors, such as IL-1066. However, that study was performed in a C57BL/6 
 BALB/c model of acute GVHD, where defining characteristics of the disease include 
acute inflammation and early alloreactive damage to the tissues, along with rapid disease 
onset, progression and mortality from acute GVHD. In contrast, chronic GVHD is often 
defined by inappropriate and prolonged inflammation alongside anti-inflammatory “wound 
healing” responses and fibrosis. Therefore, we believe that the mast cell, while beneficial 
in the inflammatory phase of aGVHD, ultimately becomes detrimental in cGVHD through 
25 
 
its ongoing anti-inflammatory activities resulting in collagen deposition and pathogenic 
fibrosis. 
Chemokine production by innate immune cells is a key mediator of  increased tissue 
recruitment of other innate cells as well as alloreactive adaptive cells. The T-cell 
chemoattractants CCL5, CXCL9, CXCL10, and CXCL11 are considered to be some of the 
most consistent disease biomarkers in both acute and chronic GVHD35,67. Furthermore, 
without CCR1/CCL5 signaling, donor T-cells have been shown to have greatly decreased 
proliferation and IFN-gamma secretion68. This indicates that these molecules are not only 
important for inducing migration in T-cells, but that they help prime functional activity as 
well.  
1.6 Therapeutic options in graft-versus-host disease 
Treatment options in GVHD are initially  focused on preventing and treating the 
acute phase of the disease. Methotrexate and cyclosporine/tacrolimus are often used for 
GVHD prophylaxis. More recently, and particularly in the setting of haploidentical 
transplants, post-transplant cyclophosphamide is used to reduce early GVHD and to 
suppress and cause cellular dysfunction in alloreactive clones15. Patients who develop 
grades III-IV acute GVHD have a very poor survival, with one study reporting an 8 percent 
5-year survival rate69. Therefore, minimization of disease burden is crucial, and 
corticosteroids or broad-spectrum immunosuppressants are first-line therapies. Anti-
thymocyte globulin is also used to suppress T-cell responses, especially in patients 
refractory to corticosteroids.  
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A major challenge with immunosuppression is the loss of the GVL effect, since 
immunosuppressants reduce donor immunosurveillance. Patients also suffer from higher 
rates of stem cell engraftment failure when dosed with increasing doses of 
immunosuppressant. Therefore, it is necessary to taper a patient’s dose of 
immunosuppressants as soon as clinically possible7. cGVHD is also treated primarily using 
immunosuppressive and anti-inflammatory approaches, yet responses are not satisfactory 
and long-term treatment is associated with poor tolerability and risk of severe and 
potentially lethal infections. 
cGVHD has recently seen several treatment options become available, especially 
small molecule tyrosine kinase or Jak-Stat pathway inhibitors. Ibrutinib (trade name: 
Imbruvica) was shown to be effective at inhibiting GVHD progression in murine models 
of sclerodermatic and pulmonary GVHD34, after which it moved on to human trials and 
received FDA approval in 201770,71. Ruxolitinib (trade name: Jakafi) is a Jak1 and Jak2 
inhibitor, proteins which serve as signal transduction molecules downstream of some 
cytokine receptors, such as the Type I IFN receptor. Ruxolitinib was recently approved for 
steroid-refractory aGVHD and is currently in phase III clinical trials for steroid-refractory 
chronic GVHD72,73.   
 Overall, there is a clear need for a better clinical armamentarium for both acute and 
chronic GVHD. Immunosuppression does not always sufficiently repress aGVHD and 
does not reduce incidence or severity of cGVHD, in addition to opening the door to 
potentially lethal infections or relapse of primary disease. Next-generation drugs such as 
ibrutinib and ruxolitinib show promise, but further work is needed to verify the patient 
populations in which they can be of the most use.  
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1.7 Mast cells 
Mast cells are myeloid granulocytes traditionally defined by their role in allergy 
through release of proinflammatory mediators such as histamine and heparin. Mast cells 
differentiate in the bone marrow from CD34+ progenitor cells, then travel to and mature in 
tissue. These long-lived cells then remain in the tissue, where they are involved in 
immunosurveillance, wound healing, and defense against helminth parasites74.  
After staining with toluidine blue, mast cells are visually striking and easy to 
identify, being filled with azurophilic granules containing a wide variety of mediators 
including histamine, heparin, prostaglandins, and proteases such as tryptase and chymase. 
These granules are released upon binding of IgE and a cross-linking antigen to the 
immunoglobulin E (IgE)/FcεRIα complex. This initiates a signaling cascade leading to 
release of preformed granules as well as inducing de novo synthesis and concomitant 
release of a wide array of extracellular mediators including cytokines, chemokines, and 
growth factors. Without this IgE/antigen crosslinking, mast cells will have a drastically 
reduced response to other stimuli75.  
However, mast cells can also be activated by other methods. Of particular interest 
in GVHD may be IL-33-based mast cell activation. IL-33 is produced by damaged tissues 
and binds to ST2 on the surface of the mast cell, inducing degranulation and synthesis of 
an array of cytokines and chemokines largely distinct from those produced during IgE-
mediated degranulation. The particular products secreted by mast cells vary based on 
location and surroundings, with the cytokine profile present in the microenvironment 
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largely determining which proteins are expressed upon degranulation. For instance, in an 
inflammatory environment, mast cells have been shown to release regulatory factors and 
to enhance Treg responses in order to equilibrate their environment75,76.   
Interestingly, the skin and lungs are some of the primary tissue niches for mast 
cells, as well as some of the primary target organs for cGVHD, leading one to question 
whether mast cells may play a role in disease progression. Previous studies have 
demonstrated that mast cells degranulate early in cGVHD pathogenesis, the act of which 
makes histologic identification difficult and has led to the phenomenon of “phantom” mast 
cells in skin samples. Yet these mast cells still exist in situ, and as the disease progresses, 
they recover granulocyte function and once again begin acting as effector mast cells. This 
initial work was done by Henry Claman and others in the 1980’s and hinted at an initiating 
role for mast cells in the onset of cGVHD64,65,77,78. 
 
1.7.1 Role in immunity 
Mast cells are primarily known for their granules. It is the first notable feature when 
viewing the cell and was the source of its name, first defined by Paul Ehrlich in his doctoral 
thesis. Believing the granules to be a source of nutrients for surrounding cells, he christened 
them Mastzellen, meaning “fattening cells” in his native German. Today, we know those 
granules to contain a wide variety of active agents which allow mast cells to fulfill their 
myriad of roles79.  
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Canonically, the mast cell is primarily involved in helminth infection. Mast cell 
production of IL-4, IL-5, and IL-13 help to polarize the immune environment towards Type 
II immunity which is beneficial for anti-helminth immune responses80. Mast cell proteases 
can help to digest and destroy pathogens too large for normal cellular immunity to deal 
with. Additionally, histamine and other mediators produced by mast cells cause contraction 
of smooth muscle, which can assist in physical expulsion of the parasite.  
Mast cells have also been shown to be crucial for minimizing damage from 
envenomation. Most venoms are peptides, and mast cells, being preloaded with a wide 
variety of proteases in their granules, are uniquely equipped to neutralize them. Studies 
have shown that mast cell chymase, among other proteases, can neutralize venom from 
reptiles such as Gila monsters and snakes, as well as venoms involved in insect bites and 
stings80–82.  
Due to their tropism to skin and mucosal sites, mast cells are often among the first 
cells to respond to breaches in physical barriers. Mast cells express a wide variety of 
receptors, including TLRs, ST2, and various chemokine and cytokine receptors that can 
recognize tissue damage or pathogens entering the local area. Mast cell responses to 
stimulation through these receptors can range from aggressive degranulation to low-level 
but sustained cytokine production75. Chemokine production from mast cells is critically 
important for this process; mast cells are capable of recruiting a huge variety of immune 
cells including but not limited to T-cells, B-cells, neutrophils, eosinophils, and 
macrophages.  
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In addition to their role as sentinel cells, mast cells are also important for wound 
healing and repairing tissue damage. This can take place through promotion of 
angiogenesis by VEGF, bFGF, and TGF-beta79. Histamine also increases vascular 
permeability and allows for increased recruitment of cells that contribute to sterilization of 
the injury site. Additionally, mast cells are involved in wound healing, both directly and 
indirectly. Mast cell proteases chew back the damaged tissue, while mast cell interactions 
with fibroblasts induce proliferation, myofibroblast differentiation, and collagen 
deposition, which promote wound closure and tissue remodeling83. 
 
1.7.2 Pathologies 
Despite the beneficial aspects of mast cells in immunity, they are often 
characterized more by their detrimental effects. Nearly everyone has experience with mast 
cells in the context of allergy; any time someone takes an antihistamine, they are aiming to 
inhibit mast cell responses. However, mast cells can also be detrimental in other contexts, 
especially where there are other aspects of immune dysregulation.  
 For decades, mast cells have primarily been thought of for their role in 
allergic inflammation. Mast cell activation is shown to be chronic and prolonged in 
asthmatic patients, and those with chronic itch and urticaria also have pathologic mast cell 
responses84. Mast cell involvement in allergic disease can often be detected by 
measurement of serum tryptase levels. However, this comes with a caveat; tissue-localized 
mast cells have to produce massive amounts of tryptase for it to be present in detectable 
levels in the serum, therefore this test can be subject to false-negative results.  
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Asthma is one of the most common chronic diseases in the world, and mast cells 
are critical in both the initial anaphylactic response as well as the later stages of airway 
remodeling77,85,86. Mast cell histamine and TNF-alpha induces smooth muscle contraction 
and swelling, which can lead to airway obstruction. IL-4 and IL-13 produced by mast cells 
induce B-cell class switching to IgE which can lead to anti-allergen IgE responses, 
sensitizing a patient to further exposure. Additionally, in the context of chronic 
inflammation, B-cells can produce IgE autoantibodies, kicking off a positive feedback 
loops of IgE/mast cell driven inflammation. Additionally, mast cell growth factor and 
tryptase production can lead to airway remodeling by restrictive thickening of the basement 
membrane and hyper-production of mucus86.  
Mast cells are also implicated in diseases outside of allergy. For instance, defective 
wound healing responses and pathological fibrosis have been shown to be mast cell 
dependent in many diseases or model systems77,85,87–89. These responses make sense when 
considered alongside the physiological roles of mast cells; wound healing and angiogenic 
responses are known to function poorly when taking place during chronic inflammation 
such as that seen in cGVHD.  
 
1.8 Overall Hypothesis 
cGVHD is a debilitating disease and much of its symptomology is due to 
pathogenic fibrosis. This proposal aims to determine the mechanism by which this 
pathogenic fibrosis is propagated, the understanding of which is currently very limited. The 
identification of mast cells as potential initiators of fibrosis in cGVHD would tie together 
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many disparate threads in the study of GVHD, as the transition from acute to chronic 
GVHD, or even the rise of de novo chronic GVHD, is complex and incompletely 
understood. We hypothesize that mast cells in the tissue contribute to the pathogenesis of 
dermal manifestations of chronic graft-versus-host disease through chemokine production 
and establishment of a profibrotic environment. We further hypothesize that mast cells 
propagating cGVHD of the skin are of recipient origin due their mature developmental 
stage and low susceptibility to radiation induced death. 
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CHAPTER 2. MATERIALS AND METHODS 
2.1 Animals 
All animal work was approved by the University of Kentucky Institutional Animal 
Care and Use Committee and the Department of Laboratory Animal Resources, protocol 
number 2016-2488. BALB/cJ, LP/J, C57BL/6J, and B6.Cg-KitW-sh/HNihrJaeBsmGlliJ 
mice were all purchased from commercially available sources (Stock numbers 000651 
(RRID IMSR_JAX:000651), 000676 (RRID IMSR_JAX:000676), 000664 (RRID 
IMSR_JAX:000664), and 012861 (RRID MMRRC_012861-UCD), respectively. Jackson 
Laboratories, Bar Harbor, ME, USA). To minimize gender effects on this mechanistic 
study, all mice were female and were used at 8-10 weeks of age. 
 
2.2 Hematopoietic transplantation model 
C57BL/6J, B6.Cg-KitW-sh/HNihrJaeBsmGlliJ, or LP/J donor mice were sacrificed 
by CO2 inhalation, then bone marrow cells and splenocytes were isolated and counted. 
C57BL/6J and B6.Cg-KitW-sh/HNihrJaeBsmGlliJ recipients were exposed to a single dose 
of 850cGy of ionizing radiation from a Cesium source, then injected intravenously with 
2.0x106 LP/J splenocytes and 5.0x106 LP/J bone marrow cells. Alternatively, mice were 
conditioned with busulfan/cyclophosphamide as previously described, adapted to our 
chronic GVHD model90. Briefly, mice were injected intraperitoneally for 5 days with 
busulfan from day -7 to -3 at 15mg/kg. Cyclophosphamide dosing at 100mg/kg took place 
for two days alongside busulfan on days -4 and -3. Mice were then given two days to rest 
without dosing prior to injection of donor cells at the same dose as in the TBI model. In 
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the syngeneic group, C57BL/6J mice received the same dose of splenocytes and bone 
marrow cells from a C57BL/6J mouse. After week 7, blood was collected into heparinized 
tubes (365965, BD Biosciences, San Jose, CA). Heparin tubes were centrifuged at 1500xG 
for 10 minutes, then plasma was harvested and stored at -80C. Skin, lung, liver, small 
intestine, colon, kidneys, ear, and tracheal tissue were harvested, trisected, and stored either 
in formalin for histologic analysis, in RNALater (AM7021 , Millipore-Sigma, St. Louis, 
MO) for RNA stabilization, or snap-frozen over dry ice for protein analysis, then stored at 
-80°C. Splenocytes were harvested for flow cytometric analysis. 
 
2.3 GVHD scoring 
Recipient mice were monitored daily for survival, and clinical GVHD was assessed 
weekly by a lab member not directly involved in the planning of the study. Mice were 
scored for GVHD by assessment of five clinical parameters: weight loss, posture 
(hunching), activity, fur texture, and skin integrity. Individual mice from coded cages 
received a score of 0 to 2 for each criterion (maximum score of 10) that was used as an 
index of severity and progression of disease55. 
 
2.4 Mast cell culture 
Bone marrow was extracted from femurs and tibias isolated from BALB/cJ or 
C57BL/6J mice and cultured in DMEM media (12-604F, Lonza, Basel, Switzerland) with 
10% heat-inactivated fetal bovine serum (35-011-CV, Corning Inc., Corning, NY) and 1% 
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penicillin/streptomycin (120-095-721EA, Quality Biological, Gaithersburg, MD) at 37C, 
5% CO2, in a humidified incubator. After 24 hours, the suspension cells were removed and 
cultured in a new flask along with 10ng/ml recombinant murine IL-3 (213-13, Peprotech, 
Rocky Hill, NJ). Cells were passaged twice per week, each time leaving behind any 
adherent cells. After 4-6 weeks, cell phenotype was confirmed by visual morphology and 
flow cytometry. 
 
2.5 Mast cell irradiation/chemotherapy viability assay 
Viable mast cells were counted by hemacytometer via trypan blue exclusion and 
plated at 1e6/ml, then exposed to 8.5 or 20Gy single-dose radiation from a cesium source 
or chemotherapeutic agents. Busulfan and cyclophosphamide were purchased from 
Cayman Chemicals (14843 and 13849, Ann Arbor, MI) and resuspended in DMSO. 
Drugging time and conditions were chosen based on clinical usage91. Cells were drugged 
with 800ng/ml busulfan and/or 30ug/ml cyclophosphamide, which corresponded to steady-
state serum levels of the drug during clinical utilization91. Cells were approximately 98% 
viable prior to irradiation. Every 24 hours, cells were counted and assessed for viability by 
trypan blue exclusion out to 96 hours post-irradiation or 72 hours post-drugging. 
 
2.6 Mast cell stimulation and inhibition assays 
Mast cells were incubated overnight with 100ng/ml murine monoclonal anti-DNP 
IgE, clone SPE-7 (D8406, RRID:AB_259249, Millipore-Sigma, St. Louis, MO) at 37C. 
36 
 
The next day, cells were centrifuged and washed twice with fresh media to remove 
unbound IgE and cells were replated in fresh media with 10ng/ml IL-3. Stimulation was 
added to the relevant wells in the form of 10ng/ml IL-33 and/or 100ng/ml DNP-BSA for 
24 hours at 37C, then cells were centrifuged and supernatant was collected. For the drug 
inhibition assays, ibrutinib, ruxolitinib, imatinib, and fingolimod were purchased from 
Cayman Chemical (936563-96-1, 941678-49-5, 220127-57-1, 162359-55-9, Ann Arbor, 
MI) and reconstituted per the manufacturer’s instructions. Drug stocks were diluted in 
media and incubated with mast cells after the overnight IgE incubation step. Cells were 
treated for one hour at 37C, then washed out with fresh media twice. Cells were then 
stimulated as per above. 
 
2.7 Degranulation by CD107a expression 
Cells were incubated at 1e6/ml with IgE overnight then washed and plated in new 
media, as above. 0.66ul/ml Golgistop (554724, BD Biosciences, San Jose, CA) was added 
along with AF594-CD107a antibody, clone 1D4B, (121624, RRID:AB_2616690, 
Biolegend, San Diego, CA), then cells were stimulated with 100ng/ml DNP-BSA and/or 
50ng/ml SCF (250-03, Peprotech) for 4 hours at 37C. Cells were then collected, washed, 
and fixed/permeabilized with Fix/Perm reagent (554714, BD Biosciences). Cells were then 
stained with BV421-CD117 (clone 2B8, 105827, RRID:AB_10898120) and PE-FCeR1a 
(clone MAR-1, 134307, RRID:AB_1626104) (Biolegend) in perm/wash buffer for 20 
minutes at 4C, washed, and analyzed by flow cytometry for CD117/FCeR1a +/+ CD107 
+/- expression. 
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2.8 Histology 
Organs were collected from mice and suspended in 4% formalin for 48 hours, then 
70% ethanol for 7 days. After this, samples were cut into slices, processed, and embedded 
in paraffin blocks. All sections shown were sectioned at 5 micron thickness. Masson’s 
trichrome staining was performed according to manufacturer protocol (26367-Series, 
Electron Microscopy Sciences, Hatfield, PA). H+E stains were performed by the 
University of Kentucky Surgical Pathology core and assessed by a blinded, board-certified 
pathologist according to a previously published organ-specific GVHD scoring system50,55. 
Skin slides were stained with Toluidine Blue O (364-12, Millipore Sigma) and assessed as 
toluidine blue-positive cells per high-power field. Counts were verified by a separate, 
blinded researcher. Texas Red-conjugated avidin was purchased from Rockland 
Immunochemicals (A003-09, Limerick, PA) and resuspended at 2mg/ml in deionized 
water. This was diluted 1:500 and sections were stained for 1 hour, washed 3 times in PBS, 
dehydrated to xylene, and mounted with Fluoroshield Mounting Medium with DAPI 
(ab104139, Abcam, Boston, MA). 
 
2.9 Immunohistochemistry 
Slides were baked at 80C for 15 minutes, then rehydrated through xylene, 100%, 
95%, and 70% ethanol into H2O. Antigen retrieval was performed in citrate Target 
Retrieval Solution (S169984-2, Agilent, Santa Clara, CA), pH 6.0, in a pressure cooker. 
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Slides were blocked for 30 minutes in PowerBlock (HK083-50K, Biogenex, Fremont, CA), 
then incubated with primary antibody at a 1:200 dilution in PowerBlock. Antibodies used 
were rabbit anti-mouse CD3e, clone D4V8L (99940, RRID:AB_2755035, Cell Signaling 
Technologies, Danvers, MA), and mouse anti-human tryptase, clone AA1 (ab2378, 
RRID:AB_303023, Abcam, Boston, MA). Slides were washed in PBS + 0.1% Tween 20 
(PBS-T) and then incubated with secondary antibody. For CD3 staining, a drop of Dako 
Envision+ HRP Anti-Rabbit Polymer (K4003, RRID:AB_2630375, Agilent) was added to 
slides for one hour, then washed with PBS-T. For tryptase staining, Goat Anti-Mouse 
Immunoglobulin/HRP (P0260, RRID:AB_2636929, Agilent) was used at a 1:1 dilution for 
10 minutes and then washed with PBS-T. After washing, DAB chromogen (ab64238, 
Abcam) was prepared according to manufacturer’s instructions and added to slides while 
observing the staining under a microscope for 30 seconds (tryptase staining) or 2 minutes 
(CD3 staining). The reaction was quenched in diH2O, then dehydrated to xylene. Slides 
were mounted using Richard-Allan Scientific mounting medium (4112APG, Thermo 
Fisher Scientific, Waltham, MA). 
 
2.10 Microscopy and analysis 
Histology slides were imaged by Aperio Scanscope XT digital slide scanner or by 
a color camera system attached to a Nikon Eclipse 80i microscope. All scale bars are 
100um. Trichrome and CD3 IHC slides were digitally scanned by an Aperio ScanScope 
XT system. Dermal thickness was measured with the ruler tool across 10-20 areas of tissue. 
Aperio methodology and results were checked and verified by a blinded pathologist. CD3 
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and tryptase positivity was measured across the whole tissue by the Aperio Positive Pixel 
Count V9 algorithm. Counts were also verified by ImageJ IHC profiler analysis by a 
blinded, independent researcher. Fluorescence images were acquired on a Nikon Eclipse 
TE2000-U microscope equipped with a DS-Qi1Mc camera. 
 
2.11 Flow cytometry 
Splenocytes were phenotyped using two different antibody panels. The first panel 
consisted of lymphocyte and T-cell stains and allowed for identification of CD45, CD3, 
CD4, CD8, and FoxP3 subsets. The second panel identified B-cells, neutrophils, 
macrophages, and dendritic cells using stains for CD19, CD11c, CD11b, F4/80, and Ly6G. 
Splenic tissue was forced through a 70 micron filter to create a single cell suspension and 
cells were washed with PBS containing 4% FBS and incubated with FcR-block anti-mouse 
CD16/CD32 (14-0161-82, RRID:AB_467133, Clone 93, eBioscience, San Diego, CA). 
Cells then were incubated in a pre-optimized concentration of antibodies in a total volume 
of 100μL. For intracellular staining for FoxP3, fixation and permeabilization were done as 
per protocol using the fixation/permeabilization concentrate and diluent (00-5123-43, 
eBioscience). The following antibody clones were used for splenocyte characterization:  
FITC-CD3 (REA641, 130-119-798, RRID:AB_2751851), APC-CD4 (GK1.5, 130-
091-611, RRID:AB_871692), APC-Vio770-CD45 (30F11, 130-118-687, 
RRID:AB_2733121), APC-CD11c (N418, 130-091-844, RRID:AB_244272), PE-CD19 
(6D5, 130-092-041, RRID:AB_871638), FITC-F4/80 (REA126, 130-102-988, 
RRID:AB_2651700) (Miltenyi Biotec, Bergisch Gladbach, Germany) 
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PerCP-Cy5.5-CD11b (M1/70, 101228, RRID:AB_893232), PerCP-Cy5.5-CD8 
(53-6.7, 100733, RRID:AB_2075239) (Biolegend, San Jose, CA) 
PE-Cy7-Ly6G (RB6-8C5, 25-5931-81, RRID:AB_469662), APC-eFluor780-
MHCII (M5/114.15.2, 47-5321-82, RRID:AB_1548783), PE-FoxP3 (FJK-16s, 12-5773-
80, RRID:AB_465935) (eBioscience) 
Mast cells were phenotyped using the following antibody clones: 
BV421-CD117 (clone 2B8, 105827, RRID:AB_10898120), PE-FCeR1a (clone 
MAR-1, 134307, RRID:AB_1626104) (Biolegend) 
All cells were analyzed on a BD LSR II cytometer (BD Biosciences) using single-
stained OneComp eBeads (01-1111-41, Thermo Fisher Scientific, Waltham, MA) to 
determine compensation values. All gates were set using fluorescence-minus-one (FMO) 
controls. Flow cytometry data were analyzed using FlowJo V10 software (FlowJo Inc., 
Ashland, OR). 
 
2.12 RNA isolation and NanoString analysis 
Tissue was frozen in RNALater as described in “Transplant” methods. The tissue 
was thawed, then suspended in 1ml of Ribozol RNA isolation solution (VWR, Radnor, 
PA), and homogenized using a Tissuemiser homogenizer (Thermo Fisher, Waltham, MA). 
RNA was isolated from the homogenate per the Ribozol manufacturer’s instructions. RNA 
was quantitated using the Qubit RNA BR assay kit in the Qubit Fluorometer (Thermo 
Fisher). 100ng of RNA was loaded into the cartridge of the NanoString Myeloid Innate 
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Immunity panel and run on the nCounter Flex system at the University of Kentucky 
Clinical Genomics core per the manufacturer’s instructions (NanoString Technologies, 
Seattle, WA). Data normalization and analysis was performed in the nSolver software. 
 
2.13 Real-time quantitative PCR 
For cDNA synthesis and qPCR, RNA was quantified using a Nanodrop instrument 
(Thermo Fisher), and 100ng was loaded into the iScript cDNA Synthesis Kit (1708891, 
Bio-Rad, Hercules, CA). For IL21 gene analysis, a predesigned primer probe mix was 
purchased from Integrated DNA Technologies (Assay ID: Mm.PT.58.7853071, Integrated 
DNA Technologies, San Jose, CA) and normalized using ACTB as a housekeeping gene 
(Assay ID: Mm.PT.39a.22214843.g). cDNA was assayed using the Luna Universal Probe 
qPCR master-mix, (M3004X, New England Biolabs, Ipswich, MA) on an Applied 
Biosystems StepOne Real-Time PCR System (Applied Biosystems, Foster City, CA). 
Relative quantitation was performed using the delta-delta CT method, described 
previously92. 
 
2.14 Tissue lysate preparation 
Tissue was snap-frozen on dry ice as described in the “Transplant” methods section. 
The tissue was thawed, then suspended in 500ml 1x RIPA buffer (89900, Thermo Fisher, 
Waltham, MA) with protease inhibitors added (cOmplete Protease Inhibitor Cocktail, 
4693159001, Roche, Basel, Switzerland). Tissue was homogenized using a Tissuemiser 
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homogenizer (Thermo Fisher). Homogenate was vortexed for 30 seconds, then put on ice 
for 10 minutes. This procedure was repeated 3 times, then homogenates were spun down 
at 14,000xG for 10 minutes at 4C. Supernatant was moved to a new tube and quantified by 
Pierce BCA protein assay kit (23225, Thermo Fisher). 
 
2.15 Measurement of cytokines and chemokines 
The levels of TNF-α, IL-6, IFN-γ, IL-2, IL-4, IL-10 and IL-17α were determined 
in plasma samples through the Mouse Th1/Th2/Th17 Cytometric Bead Array kit (560485, 
BD Biosciences, San Jose, CA). Bead fluorescence was measured using the BD 
Biosciences LSRII flow cytometer and analyzed with the accompanying software. Protein 
levels of CCL5, CCL11, CCL17, CXCL1, CXCL9, CXCL10, CXCL13, CXCL5, CCL22, 
CCL2, CCL3, and CCL4 in tissue and mast cell supernatants were analyzed with the 
LEGENDplex Mouse Proinflammatory Chemokine Panel (740007, Biolegend) per the 
manufacturer’s instructions. Supernatants were loaded without dilution. 100 micrograms 
of tissue lysate were loaded for analysis of chemokine levels in the skin, although final 
values displayed in the paper were normalized to picograms per milliliter per microgram 
of protein loaded. Bead fluorescence was measured using the BD Biosciences LSRII flow 
cytometer and analyzed in the Biolegend LEGENDplex data analysis software. 
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2.16 Fibroblast proliferation assay 
Fibroblasts were cultured from the skin of C57BL/6J mice as previously described 
by Seluanov et al93. After 3 weeks of culture, cells were nearly confluent in a 10cm petri 
dish. Media was aspirated off and 3 milliliters of trypsin was added to the dish for 5 
minutes. After 5 minutes, cells were scraped off using a sterile scraper and spun down at 
350xG for 5 minutes. Cells were resuspended in 6 milliliters and plated equally into a 6 
well plate in DMEM + 10% FBS + 1% penicillin/streptomycin. After 4 hours to allow the 
cells to adhere, cells were counted on an inverted microscope across 4 fields of view per 
well at 200x magnification. At this point, 1ml of mast cell supernatants or fresh media was 
added to the 1ml of culture in each well. Cells were counted again 24 hours later, and again 
after 48 hours.  
2.17 Human tissue samples 
All GVHD samples were from patients at the University of Kentucky Markey 
Cancer Center who had undergone an allo-HSCT with a subsequent diagnosis of chronic 
GVHD. Chart review and sample acquisition was performed by the honest broker of the 
University of Kentucky Biospecimen Procurement and Translational Pathology Core and 
samples were sectioned from paraffin-embedded tissue. All normal and cGVHD skin 
samples were derived from surgical specimens left over from clinical care that were banked 
by the UK Biospecimen Procurement Core under a waiver of consent from the UK IRB. 
All samples were deidentified and were not able to be linked to patient records by any 
investigators involved in the study. As a result of this, the University of Kentucky 
Institutional Review Board deemed that these samples did not meet the Department of 
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Health and Human Services (DHHS) definition of human subjects or the Food & Drug 
Administration’s (FDA) definition of human subjects. 
 
2.18 Figure preparation and statistics 
All figures were prepared in GraphPad Prism 6 and 7 (GraphPad, San Diego, CA), 
FlowJo V10 (FlowJo Inc., Ashland, OR), or NanoString nSolver (NanoString 
Technologies, Seattle, WA) software packages. Experimental data are expressed as means 
± standard deviation unless noted otherwise in the figure legend. Differences between two 
groups were analyzed by the two-tailed independent t-test. Differences between three or 
more groups were analyzed by one-way ANOVA, with a Tukey’s post-hoc multiple 
comparisons test to determine the significance between groups. P values ≤0.05 were 
considered statistically significant. P value 0.01 to 0.05 = *, P value 0.001 to 0.01 = **, P 
value 0.0001 to 0.001 = ***, P value <0.0001 = ****, NS = not significant 
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CHAPTER 3. MAST CELLS SURVIVE AND ARE FUNCTIONAL AFTER IONIZING 
RADIATION AND CHEMOTHERAPY 
3.1 Introduction 
The conditioning regimen given to a patient is a key step in the process of HSCT. 
In an idealized transplant, this regimen, usually consisting of chemotherapy, radiation, or 
a combination of both, serves multiple purposes. First, it ablates the recipient bone marrow, 
creating hematologic “space” for the donor stem cells to engraft and grow. Second, it 
eliminates recipient-derived immune cells, either in circulation or in the tissues. This 
allows the donor immune cells to reconstitute in an environment where they can grow to 
maturity properly without undue influence from the host immune system. Lastly, 
conditioning also immunosuppresses the recipient; any cells that survive conditioning are 
damaged and incapable of mounting an immune response, therefore allowing them to be 
cleared by the nascent donor-derived immune system as it reconstitutes from the marrow11. 
Crucially, this process allows for engraftment to function properly, as the donor cells would 
otherwise be recognized as non-self and cleared by the recipient immune system.  
However, not all recipient-derived cells are cleared during conditioning. Cells in 
the tissues can sometimes survive, either by virtue of being slowly replicating cells that are 
less affected by chemotherapy or by receiving a lesser dose due to their tissue 
localization11,30. An example of this is recipient-derived antigen-presenting cells, which are 
activated shortly after transplant and present self-antigens to donor immune cells from the 
graft which then further activate the APCs, a classic pathophysiology loop in the induction 
of acute GVHD. Additionally, incomplete suppression of recipient bone marrow can lead 
to long-term chimerism due to continual production of host hematopoietic cells from the 
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marrow. These scenarios are acknowledged, but conditioning is still widely considered to 
eliminate the vast majority of recipient-derived immune cells94.  
In previous studies, mast cells had been shown to be surprisingly resilient to 
radiation95. However, most of these studies used lower doses of radiation than are 
commonly implemented in pre-HSCT conditioning. Additionally, there is little data on the 
effect of chemotherapeutic alkylating agents on mast cells, and what data exists has often 
been generated in the context of canine mast cell tumors96. Given the possibility of mast 
cells as profibrotic and pathogenic cells in cGVHD, we therefore sought to determine 
whether mast cells, in vitro, may be resistant to the types of challenges seen during pre-
transplant conditioning.  
3.2 Results 
3.2.1 Mast cells survive exposure to radiation and chemotherapeutic agents 
Previous literature by several groups indicated that mast cells might be capable of 
surviving high doses of ionizing radiation, such as that used in conditioning prior to 
transplant of donor cells64,95,97. To determine this, we derived mast cells ex vivo from 
murine bone marrow precursors from both BALB/cJ and C57BL/6J mice. After 4-6 weeks 
of culture, these cells displayed morphological similarity to mast cells, and at least 97 
percent displayed the characteristic markers of mast cells, FCeR1a/cKit +/+ by flow 
cytometry (Figure 3.1). 
We then tested the viability and overall number of these cells after they were treated 
with either 8.5 or 20 Gy of ionizing radiation. Mast cells from either C57BL/6J or BALB/cJ 
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mice showed no change from baseline after 96 hours of culture, implying that mast cells 
are highly resistant to cell death induced by ionizing radiation (Figure 3.2). Rather than 
total body irradiation (TBI), chemotherapy-based regimens are often used clinically. We 
tested whether mast cells could survive a common chemotherapy-based conditioning 
regimen of busulfan and cyclophosphamide. We saw that in all groups, using both radiation 
and chemotherapeutic agents, mast cell viability was unaffected and cell count increased 
after 10 days, implying a low level of cell proliferation. Doses were picked based on 
clinically achievable steady-state serum concentrations91,98. 
3.2.2 Mast cells are still functional and capable of degranulation after irradiation 
Since total body irradiation is the conditioning regimen used in almost all murine 
models, we then tested whether mast cells would remain functional after irradiation. 
CD107a is a protein involved in vesicle trafficking and function and is expressed on the 
inner leaflet of vesicles. After these vesicles dock with the membrane, CD107a is 
detectable on the cell surface. Therefore, a greater degree of mast cell degranulation 
induces higher CD107a expression99. Degranulation in response to FCeR1a receptor 
crosslinking was measured by CD107a expression on the cell surface. Degranulation was 
apparent at all doses and was unaffected by ionizing radiation (Figure 3.4). 
3.3 Discussion 
Our data demonstrating mast cell viability and functionality after conditioning  
(Figures 3.1-3.4) confirm several earlier studies showing similar results95,100. However, 
while previous work merely showed that mast cells initially survive irradiation, these 
experiments expand on this considerably; not only do we show that mast cells survive both 
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irradiation and chemotherapeutic agents, but we also show that these challenges leave the 
mast cell unaffected in terms of viability, proliferative capacity, or function.  
This resistance of mast cells is striking in contrast to many other immune cell types, 
which are considered to be depleted during the conditioning phase of allo-HSCT44. 
However, MC resistance to chemotherapeutic alkylating agents is perhaps not entirely 
surprising. They express high levels of aldehyde dehydrogenase, which is known to inhibit 
the activity of alkylating agents, and divide slowly101–103. Yet their ability to survive and 
proliferate even after chemotherapy or 20Gy of radiation is itself unexpected. Taken 
together, this implies that the mast cell is a conditioning-resistant, mature, immune effector 
cell, which remains functional and that has tropism towards selected cGVHD target organs. 
These data lend credence to our hypothesis that recipient-derived mast cells may play a 
role in the pathogenesis of chronic GVHD. 
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Figure 3.1: Mast cells can be cultured ex vivo from murine bone marrow at high purity  
Bone marrow was isolated from C57BL/6J mice under sterile conditions. Marrow was 
cultured in DMEM media with 10ng/ml IL-3 for at least 4 weeks. Flow cytometry analysis 
of bone marrow-derived mast cells after 4-6 weeks of culture, displaying marker expression 
characteristic of mast cells and high purity. 
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Figure 3.2: Mast cells survive after exposure to ionizing radiation 
Cultured mast cells from either C57BL/6J or Balb/CJ mice were exposed to the listed doses 
of ionizing radiation. Mast cell viability (A) and count (B) are shown for each day. There 
was no significant change from baseline even 96 hr. after irradiation. Graphs are combined 
data from 3 independent experiments. 
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Figure 3.3: Mast cells survive and proliferate after exposure to ionizing radiation or 
chemotherapeutic agents. 
Mast cells cultured from C57BL/6J mice were exposed to the listed doses of radiation, 
chemotherapeutic agents, or the combination thereof. Radiation exposure was single dose, 
and chemotherapeutic agents were dosed prior to treatment and then left in culture. 
Viability (A) and cell count (B) were assessed daily. There was no significant change in 
viability across any treatment group, while all cell counts increased after ten days. Data 
shown is the combination of 2 separate experiments.   
A 
B 
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Figure 3.4: Mast cells are still functional after exposure to ionizing radiation 
Since irradiation is the conditioning regimen used in most murine models, we then tested 
whether mast cells would remain functional after irradiation. Degranulation in response to 
FCeR1a receptor crosslinking was measured by CD107a expression on the cell surface 
after 4 hours. Degranulation was apparent at all doses and was unaffected by ionizing 
radiation (quantified in A, representative flow plots in B).  
A 
B 
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CHAPTER 4. MAST CELLS ARE SIGNIFICANT CONTRIBUTORS IN A MURINE 
MODEL OF SCLERODERMATOUS DERMAL CHRONIC GRAFT VERSUS 
HOST DISEASE 
4.1 Introduction 
Our previous experiments have demonstrated that mast cells remain viable and 
functional after undergoing procedures designed to replicate pre-transplant conditioning in 
vitro. However, while this supports the possibility of mast cell involvement in the 
pathogenesis of GVHD, it does not tell us anything about what would happen to mast cells 
in a more physiological context. To further analyze the role of mast cells in GVHD, in vivo 
models are necessary.  
The dichotomy of acute vs. chronic GVHD introduces additional complication. 
Some cell types have a clearly defined role during pathogenesis of one form of the disease 
(such as recipient-derived antigen presenting cells in acute GVHD onset), but their 
contribution in other contexts is unknown or unclear. To that end, we attempted to search 
for any previous literature that examined mast cells in the course of GVHD. Initial findings 
were of great interest; in the 1980’s Henry Claman and others published an article 
discussing the disappearance of mast cells during the onset of cGVHD64. While this 
initially had a chilling effect on our hypothesis, further reading revealed a follow up study 
by the same group. They reported that the mast cells had not, in fact, disappeared, but were 
present and had degranulated, making them difficult to detect by the techniques at the 
time97. This fit nicely with our hypothesis that mast cells may survive and be active in the 
GVHD setting.  
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A continued search of previous literature led to Dr. Levi-Schaffer’s body of work, 
which focuses on mast cell, eosinophil, and fibroblast interactions, a feedback loop 
involving grouping of cells her lab has dubbed the “allergic effector unit” (AEU)104. This 
process begins with mast cell activation and leads to eosinophil recruitment and fibroblast 
activation, ultimately ending in pathogenic fibrosis throughout the affected organ system, 
an outcome that looks similar to fibrotic chronic GVHD. In the early 1990’s, Dr. Levi-
Schaffer, using Henry Claman’s work as a basis, began to examine the dynamics of mast 
cell activation in cGVHD. Using murine mast cells in vitro, she established a system 
wherein she would coculture the mast cells with splenic supernatants from mice that had 
established cGVHD. These coculture systems induced mast cell activation and 
degranulation, implying that something in the splenic environment during cGVHD is 
strongly capable of activating mast cells105. Expanding on this, when she isolated 
fibroblasts from mice with cGVHD and cocultured them with mast cells, she saw mast cell 
proliferation and activation78. Given that we now understand the AEU to begin with mast 
cells and end with fibroblast activation, this hinted at a possible feedback loop of mast cell 
and fibroblast activation in cGVHD. However, as seminal and striking as these studies 
were, they still had not examined the role of mast cells in vivo in cGVHD.  
After Dr. Levi-Schaffer’s work, mast cells in GVHD were subject to minimal study 
for approximately two decades. At least in part, this was due to a lack of effective models 
of mast cell deficiency. However, as better models were developed, the possibilities of this 
area of study began to show themselves. In 2013, Leveson-Gower et al. examined mast 
cells in the setting of fully MHC-mismatched acute GVHD66. Using mast cell-deficient 
mice alongside MC-deficient mice that had mast cells engrafted back in, they examined 
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their survival after allogeneic transplant. Mast cell deficiency was found to result in worse 
outcomes in an IL-10 dependent mechanism. The authors concluded that mast cells were 
immunoregulatory in the acute GVHD setting, especially through mast cell production of 
anti-inflammatory IL-10. However, the authors were unable to replicate IL-10 production 
by mast cells in vitro, and while the in vivo evidence supports their conclusions, further 
study is needed to determine the cytokine milieu which will induce IL-10 from mast cells.  
This study was of interest, particularly for its non-canonical role for mast cells as 
immunoregulatory cells. Further, where aGVHD is characterized by acute inflammation, 
cGVHD can be thought of as a misguided, aberrant, and eventually pathogenic attempt by 
the immune system to heal the damage done and downregulate the inflammatory response. 
Therefore, we hypothesized that this regulatory mast cell response, helpful in aGVHD, 
could eventually result in some of the pathologies seen in cGVHD. 
To assess this, we looked for a model of cGVHD that would allow us to use MC-
deficient mice as recipients in an allogeneic transplant (allo-MCd) alongside WT mice 
(allo-WT)106. The addition of a syngeneic transplant would serve as a negative control for 
disease progression. Under these constraints, the only available model of cGVHD was the 
LP/J  C57BL/6 model, which displays sclerodermatous skin disease and diffuse 
inflammation over 4-12 weeks post-transplant53. Sclerodermatous cGVHD was a good 
candidate for mast cell involvement, as multiple prior studies had linked mast cells to skin 
fibrosis in other model systems.  
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4.2 Results 
4.2.1 Skin mast cells were correlated with severely increased cGVHD and skin 
pathology after murine allogeneic transplant 
We induced cGVHD in vivo using a minor histocompatibility mismatched murine 
bone marrow transplant model (LP/J  C57BL/6J)53, illustrated in Figure 4.1. Allogeneic 
bone marrow transplants were performed into both wild type C57BL/6J (allo-WT) and 
B6.Cg-KitW-sh/HNihrJaeBsmGlliJ mast cell-deficient mice (allo-MCd). Syngeneic 
transplant recipients did not develop cGVHD and served as a negative controls. At 7 weeks 
post-transplant, 18.75% of the allo-WT group had died, while there were no deaths in either 
the syngeneic or the allo-MCd mice (Figure 4.2A). Using a previously-published whole-
animal GVHD scoring system55, we saw significant decreases in GVHD scoring in allo-
MCd mice as compared to allo-WT mice by week 5 (Figure 4.2B). While this scoring 
system was initially designed for acute GVHD, it also assesses skin and fur integrity and 
is thus suitable for our model. 
The mice were sacrificed and analyzed after week 7 post-transplant. Syngeneic 
mice had almost no skin pathology. However, allogeneic transplantation induced severe 
skin pathology in WT mice, which was significantly ameliorated in allo-MCd mice, as 
scored by an independent, blinded, board-certified pathologist (hematoxylin and eosin 
[H+E] staining, Figure 4.3A). In the allo-WT but not the syngeneic or allo-MCd animals, 
pathology scores significantly correlated with clinical GVHD scores (Figure 4.3B). In the 
lung, small intestine, liver, and colon, there were no significant pathologic differences 
between the allogeneic groups (Figure 4.3C). Only mice in the allo-WT group displayed 
clinical symptoms consistent with sclerotic chronic GVHD, including scaly skin, hair loss, 
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and patchy lesioning44.  When skin from these mice was examined histologically by 
Masson’s trichrome staining, fibrotic cGVHD was evident only in the allo-WT group, 
including excess collagen deposition, hyperkeratosis, epidermal disruption, and significant 
increases in dermal thickness107 as shown by representative images and the corresponding 
quantification in Figure 4.4. Importantly, no cGVHD was noted in the allo-MCd mice. 
4.2.2 Molecular evidence demonstrates a pro-fibrotic phenotype alongside activated 
mast cells after allogeneic transplant 
We next analyzed RNA extracted from skin of mice from each group by the 
NanoString Myeloid Innate Immunity panel or by qPCR for IL21 (not included in the 
NanoString panel). Significant increases in expression of genes associated with skin 
fibrosis were evident in the allo-WT group, each of which was significantly lowered in the 
allo-MCd group (Figure 4.5)57,108. Taken alongside the histologic data, this indicates a mast 
cell-dependent induction of fibrosis. Additionally, when skin from all groups was 
examined by fluorescent microscopy, mast cells displayed an activated and degranulated 
phenotype, but only in the allo-WT group (Figure 4.6). 
Since fibroblasts are the main effector cell responsible for collagen deposition and 
fibrosis, we assessed whether supernatants from mast cells could affect the proliferation of 
fibroblasts109. We isolated and cultured fibroblasts derived from the skin of naïve 
C57BL/6J mice for 2-3 weeks. Following trypsinization, these cells were transferred to a 
6 well plate. After 4 hours to allow cells to adhere, there were no differences in count 
between groups. We then added fresh media or conditioned media from mast cells 
stimulated under various conditions to these cultures and counted them after 24 and 48 
hours. We saw that after 24 hours, fibroblasts cultured in conditioned media from activated 
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mast cells (IgE + antigen + SCF) had grown significantly more than fibroblasts incubated 
with conditioned media from unstimulated mast cells or from mast cells incubated with 
IgE but without antigen. By 48 hours post-plating, fibroblasts cultured in conditioned 
media from activated mast cells showed a significant increase in cell count compared to all 
other conditions (Figure 4.7). This indicates that products from activated mast cells can 
induce fibroblast proliferation which could lead to increased fibrosis in vivo. This is further 
evidence for the AEU feedback loop characterized by Dr. Levi-Schaffer104.  
4.2.3 Patients with cGVHD have increased mast cell counts in the skin 
To further examine this phenomenon in the context of human patients with 
cGVHD, we obtained approval from the University of Kentucky Institutional Review 
Board for studies on banked, deidentified human samples (see Chapter 2.17 for details). 
We used the University of Kentucky Biospecimen Procurement and Translational 
Pathology Shared Resource Facility (BPTP SRF) to identify skin biopsies from allo-HSCT 
recipients who were diagnosed with chronic GVHD and where histologic changes were 
consistent with dermal graft-versus-host disease. Patient characteristics are included in 
Table 4.1. GVHD prophylaxis and antibiotic regimens were unable to be determined from 
the available anonymized patient data. Notably, nearly all patient samples had undergone 
conditioning using Bu/Cy (busulfan/cyclophosphamide) as used in Figure 3.3. Samples 
from 5 cGVHD patients were stained with Masson’s trichrome alongside skin samples 
from patients without cGVHD. Epidermal thickness was measured by Masson’s trichrome 
staining and found to be increased due to collagen deposition, consistent with cGVHD 
symptomology (Figure 4.8A). We identified levels of tryptase-positive cells in the skin by 
immunohistochemistry in order to quantify the number of mast cells present in these 
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samples. Tryptase-positive cells were primarily located near the dermal-epidermal junction 
and were significantly increased in cGVHD patients as compared to normal skin samples 
as measured by Aperio (Figure 4.8B). Quantification was verified by a blinded independent 
researcher.  Representative images for the staining are shown in Figure 4.8C. These data 
correlate with our findings that mast cells may be important in the pathogenesis of dermal 
chronic graft-versus-host disease. 
4.3 Discussion  
When assessed in the context of the data from Chapter 3, it is perhaps unsurprising 
that there was such a dichotomous difference in cGVHD symptomology in vivo between 
the allo-WT and allo-MCd groups in our murine model of allogeneic transplant. Using the 
LPJC57BL/6J model of murine cGVHD in both WT C57BL/6J and B6.Cg-KitW-
sh/HNihrJaeBsmGlliJ MC-deficient animals, we showed evidence for reductions in whole-
animal GVHD scoring, skin pathology, and in dermal thickness and fibrosis in the allo-
MCd mice (Figures 4.1-4.4). This correlated with decreases in transcript level of genes 
associated with fibrosis in the dermal environment (Figure 4.5)57,108. Additionally, our in 
vitro evidence demonstrated that mast cells are capable of producing factors that induce 
proliferation in skin-derived fibroblasts, which are responsible for collagen deposition 
(Figure 4.6). Mast cells are known to be one of the major sources of fibroblast growth 
factor, which could explain this phenomenon83. Additionally, we show that when present 
after allogeneic transplant, mast cells display striking evidence of systemic degranulation, 
data which fits alongside Henry Claman’s earlier studies64,97. 
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Previous work by Leveson-Gower et al. has shown that the presence of mast cells 
is beneficial in the context of acute GVHD through mast cell production of anti-
inflammatory factors, such as IL-1066. However, that study was performed in a 
C57BL/6BALB/c model of acute GVHD, where defining characteristics of the disease 
include acute inflammation and early alloreactive damage to the tissues, along with rapid 
disease onset, progression and mortality from acute GVHD. In contrast, chronic GVHD is 
often defined by inappropriate and prolonged inflammation alongside anti-inflammatory 
“wound healing” responses and fibrosis110. Therefore, we believe that the mast cell, while 
beneficial in the inflammatory phase of aGVHD, ultimately becomes detrimental in 
cGVHD through its ongoing anti-inflammatory activities resulting in collagen deposition 
and pathogenic fibrosis.  
These data fit with a study by Levi-Schaffer et al., which demonstrated that mast 
cells are activated by splenic supernatants from mice with cGVHD, as well as their work 
showing that fibroblasts from mice with cGVHD enhance proliferation of connective 
tissue-derived mast cells78,105. Taken together with our data showing that mast cell products 
can stimulate proliferation of fibroblasts (Figure 4.7) this could indicate a positive feedback 
loop in cGVHD wherein mast cells and fibroblasts are able to induce proliferation in the 
other cell type. In addition, there is a growing body of literature in human and murine 
models demonstrating that mast cells and fibroblasts have both direct and indirect 
interactions, the result of which is increased collagen deposition and fibrosis89,111–113.  
Lastly, we show that patients with dermal manifestations of cGVHD have higher 
overall numbers of mast cells in the skin than normal controls (Figure 4.8). This data is 
similar to what we observed in our murine model and is suggestive that mast cells may be 
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active and possibly proliferating in human cGVHD. Further studies directly or indirectly 
addressing mast cells and correlative biomarkers are warranted as these may assist 
physicians in diagnosing and predicting skin cGVHD as well as expanding the options for 
treatment.   
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Figure 4.1: Transplant layout for experiments to assess the role of mast cells in dermal 
manifestations of chronic GVHD 
cGVHD was induced in vivo through a minor histocompatibility mismatched murine bone 
marrow transplant model (LP/J  C57BL/6J)17, illustrated above. Allogeneic bone 
marrow transplants were performed using 850cGy ionizing radiation as conditioning, 
followed by bone marrow and splenocyte infusion into both wild type C57BL/6J (allo-WT) 
and B6.Cg-KitW-sh/HNihrJaeBsmGlliJ mast cell-deficient mice (allo-MCd). Syngeneic 
transplant recipients did not develop cGVHD and served as a negative control. 
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Figure 4.2: Survival and GVHD scoring of recipient mice after BMT 
A: Kaplan-Meier survival curve of syngeneic (n=6), allo-WT (n=14), and allo-MCd (n=16) 
groups after transplant. The curves are not significantly different, though the syngeneic and 
allo-MCd groups had no deaths, while the allo-WT group had 3 deaths. Data is combined 
from two independent transplants. B: Weekly GVHD scoring of syngeneic (n=6), allo-WT 
(n=16), and allo-MCd (n=14) groups after transplant. By week 5, there is a significant 
reduction in GVHD score in allo-MCd mice as compared to allo-WT mice as measured by 
a repeated-measures one-way ANOVA. Error bars are the standard error of the mean 
(SEM). P value 0.001 to 0.01 = **, P value <0.0001 = ****.  
A 
B 
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Figure 4.3: Skin pathology scoring was significantly increased in WT but not MC-
deficient mice after allogeneic transplant 
A: Skin pathology score is significantly decreased in the allo-MCd (n=16) group as 
compared to the allo-WT group (n=14). Scoring accounts for damage to the epidermis, 
dermis, subcutaneous fat, and hair follicles, as well as inflammatory infiltrate and was 
performed by a blinded pathologist. Data is combined from two independent transplants. 
B: Whole-animal GVHD scoring significantly correlates with skin pathology scoring. R 
A B 
C 
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squared and P values were determined by Spearman nonparametric correlation.  C: Organ 
pathologies in lung, small intestine, colon, and liver were not significantly different 
between groups. P value 0.01 to 0.05 = *. 
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Figure 4.4: Skin fibrosis and dermal thickening is evident in allo-WT but not allo-MCd 
animals after allogeneic transplant 
Representative images (A) and quantification (B) of Masson’s trichrome staining of skin 
from syngeneic (n=6), allo-WT (n=16), and allo-MCd (n=14) groups after transplant. Mice 
were quantified for dermal thickness according to the height of the blue collagen band 
across 10-20 different fields per mouse. Images are mice with dermal thickness closest to 
the mean values for each group. Quantification is combined data from two independent 
transplants. P value <0.0001 = ****.  
A 
B 
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Figure 4.5: Genes associated with dermal fibrosis are significantly upregulated in allo-
WT animals 
NanoString analysis or qPCR (IL21 only) were performed on RNA extracted from skin of 
mice after transplant. Significant upregulation of genes associated with dermal fibrosis are 
seen in allo-WT animals only. Syngeneic (n=3), allo-WT (n=3), and allo-MCd (n=5) mice. 
P value 0.01 to 0.05 = *, P value 0.001 to 0.01 = **, P value 0.0001 to 0.001 = ***, P value 
<0.0001 = ****. 
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Figure 4.6: Mast cells in the skin of allo-WT but not allo-MCd or syngeneic animals 
display evident degranulation 
Avidin-Texas Red staining of mast cell granules shows clear evidence of degranulation in 
skin from allo-WT animals. Granules are distributed throughout the area surrounding the 
cell nuclei (DAPI, blue) in WT animals, shown here, but this phenomenon was not seen in 
the other groups. 
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Figure 4.7: Supernatants from activated mast cells cause increased proliferation in 
fibroblasts 
Fibroblasts were isolated from murine skin and expanded. Cells were then disassociated 
and replated in plain media or with supernatants from mast cells, noted above. 48 hours 
after plating, supernatants from mast cells stimulated with IgE + antigen + 50ng/ml SCF 
caused fibroblasts to proliferate significantly more than any other condition, as measured 
by cell counting across 5 fields of view. Data is representative of two independent 
experiments. P value 0.01 to 0.05 = *. 
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Table 4.1: Characteristics of patients used in human sample analysis 
 
Characteristics of patients used in the study were determined based on anonymized data 
derived from charts of patients seen for clinical care at the University of Kentucky hospital. 
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Figure 4.8: Mast cell numbers are increased in the skin of patients with dermal 
manifestations of cGVHD  
A: Skin biopsies from patients with cGVHD displayed histologic changes consistent with 
dermal cGVHD including epidermal thickening as compared to normal controls (normal 
controls n=4, cGVHD patients n=5). B: cGVHD patient samples had a significant increase 
in tryptase staining as measured by Aperio ImageScope in the dermis as compared to 
normal controls (normal controls n=4, cGVHD patients n=5). Representative images of 
tryptase immunohistochemistry shown in (C). P value 0.01 to 0.05 = *.   
A 
B 
C 
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CHAPTER 5. MAST CELL CHEMOKINE PRODUCTION AND EFFECTOR CELL 
RECRUITMENT IS NECESSARY IN SCLERODERMATOUS GRAFT VERSUS 
HOST DISEASE 
5.1 Introduction 
Both acute and chronic GVHD share a root cause: alloreactive donor immune 
cells31. It has long been established that complete elimination of donor immune cells from 
the graft protects the recipient from GVHD, but at a cost. Without the alloreactivity from 
donor-derived immune cells in the graft, patient relapse rates are greatly increased due to 
the lack of graft-versus-leukemia effect. Therefore, the standard of care emphasizes a 
balance; complete immunosuppression is ineffective due to relapse and so close patient 
monitoring is necessary to maximize therapeutic potential while minimizing GVHD. 
Aiding clinicians in maintaining this balance are immunosuppressive agents such as 
steroids or tacrolimus114.  
Since chronic GVHD often takes place subsequent to aGVHD (or after the 
timeframe when aGVHD is common), many of the same characteristics visible in late stage 
aGVHD are visible27. Of particular relevance to this dissertation is the skin. In dermal 
cGVHD, biopsies often show significant collagen deposition and a relatively acellular 
dermis. Macrophage and T-cell infiltration is still present, but usually Th2-dominant in 
contrast to a proinflammatory Th1 profile seen in aGVHD115. Fibroblasts are abundant. 
Overall, the dermal environment is mixed; smoldering inflammation exists alongside 
aberrant wound healing responses, leading to a very profibrotic environment.  
Murine models of sclerodermatous cGVHD, such as the LP/J  C57BL/6 model 
used in our studies, display similar attributes. Immune infiltrate to the skin can be slightly 
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greater than would be seen in human patients, but the end results (collagen deposition, skin 
thickening, and pathogenic fibrosis) are largely the same53. This is driven largely by 
chemokine production from tissue-resident cells116. While macrophages are the canonical 
drivers of chemokine production, we wanted to know whether mast cells would also be 
capable of enhancing or driving these responses. Since our findings in previous chapters 
demonstrate a difference in GVHD scoring and skin pathology between WT and MC-
deficient mice, we next decided to explore the functional role of mast cells in the skin. 
5.2 Results 
5.2.1 Proinflammatory chemokine expression is significantly increased in the skin of 
WT but not mast cell-deficient mice after allogeneic transplant 
Skin from animals from each group was analyzed using the NanoString Myeloid 
Innate Immunity panel. When we looked at the subset of genes overexpressed in allo-WT 
vs. allo-MCd by PANTHER pathway analysis117, we found only one pathway to be 
statistically significant, an approximately 5-fold enrichment for the “Inflammation 
mediated by chemokine and cytokine signaling pathway” (PANTHER pathway number 
P00031, data not shown). Further analysis was performed using the NanoString nSolver 
software which clusters genes by pre-annotated pathways. Sorting on “Chemokine 
signaling genes,” heatmap analysis demonstrated an overall trend towards increased 
dermal expression of genes involved in these pathways in allo-WT mice, with lower 
expression in allo-MCd mice (Figure 5.1). We then examined expression of specific 
chemokine transcripts. CCL2, CCL3/CCL4 (which encode MIP-1a and MIP-1b, 
respectively), and CCL5 all demonstrated significant upregulation of transcript in the skin 
in allo-WT mice (Figure 5.2A). When we measured protein levels of these chemokines by 
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cytometric bead array, we saw an extremely similar expression pattern, with all 4 
chemokines upregulated in allo-WT, while syngeneic and allo-MCd were not significantly 
different (Figure 5.2B). Intriguingly, the levels of these chemokines in the allo-WT group 
were all significantly correlated with their overall GVHD score (Figure 5.3). All of these 
chemokines can be chemotactic for T-cells, the canonical GVHD effector cell118,119. 
Additionally, they are capable of recruiting monocytes, macrophages, or other myeloid 
cells, many of which are implicated in cGVHD pathogenesis and fibrotic disease.  
5.2.2 Immune infiltration and activation to the skin is ameliorated by mast cell 
deficiency  
Given the inflammation and increased chemokines evident in the skin of our allo-
WT mice, we wanted to determine whether this resulted in increased immune infiltration 
and tissue damage. Indeed, when we examined H+E-stained skin sections from allo-WT 
mice, epidermal dysregulation and an obvious dermal immune infiltrate was visible (Figure 
5.4A, quantified in Figure 5.4B). Animals from the syngeneic and allo-MCd groups 
displayed equally low levels of immune infiltrate. The immune infiltrate was characterized 
as to its hematopoietic lineage and was found to be predominantly lymphocytic in all three 
groups (Figure 5.5). Accordingly, there was no significant difference across all groups in 
eosinophil or neutrophil count in H+E-stained skin sections, nor was there a difference in 
CD19 transcript by qPCR (data not shown). All characterization and counting on H+E 
slides were performed by an independent, board-certified pathologist. 
T-cells in the skin, as measured by immunohistochemistry against CD3, were 
lessened in allo-MCd compared to allo-WT animals (Figure 5.6A). This slight but 
significant increase in cellularity was seen alongside increased gene expression of markers 
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of T-cell activation including CD69 and VAV1, as well as markers of costimulation such 
as CD80 and CD86 (Figure 5.6B). It seems that while the level of T-cell infiltration is not 
hugely different, activation and the costimulatory milieu in the dermal environment may 
enhance their effects. With this evident inflammatory infiltrate, and as the PANTHER 
analysis had also implicated inflammatory cytokine signaling in the skin, we wanted to 
analyze dermal levels of inflammatory cytokines that are often expressed by T-cells. 
Inflammatory cytokines were found to be expressed at very low levels in skin and were 
largely unchanged between groups (Figure 5.7). Of note, while the overall levels of 
cytokines were extremely low, the only cytokines that were differentially expressed 
between groups were IFN-gamma and IL-4, canonical Th1 and Th2 cytokines, 
respectively. This implies that the T-cell infiltrate in the skin is not of a homogenous 
phenotype but has mixed Th1 and Th2 potential. 
5.2.3 Mast cell production of chemokines is amenable to therapeutic intervention by 
drugs commonly used to treat sclerodermatous cGVHD 
Mast cells are known to be able to produce a wide variety of mediators, as reviewed 
excellently by Mukai et al 75. As shown in Figure 5.1, chemokine production seems to be 
a major factor in the pathogenesis of sclerodermatous GVHD in this model. Therefore, we 
wanted to test whether mast cells were capable of producing these same cytokines, assayed 
ex vivo using bone marrow-derived mast cells cultured from C57BL/6J mice.  
Indeed, we saw that upon stimulation with multiple methods of mast cell activation 
(IgE/antigen crosslinking or IgE/antigen + IL-33), mast cells produced significant amounts 
of CCL2, CCL3, and CCL4. Currently, there isonly FDA-approved drug for cGVHD, 
ibrutinib, a BTK inhibitor. Also used in cGVHD although currently in late-phase trials, 
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ruxolitinib, a Jak1/Jak2 inhibitor, has also been used by physicians with promising results. 
We examined whether these treatments, as well imatinib and fingolimod, other 
experimental drugs for cGVHD or mast cell diseases would affect mast cell chemokine 
production. Indeed, ibrutinib and ruxolitinib reduced mast cell production of these 
chemokines in a dose-dependent manner (Figure 5.8, 5.9). Treatment with imatinib or 
fingolimod did not reduce mast cell chemokine production even at the highest doses tested, 
and dosing with all drugs tested had no effect on cell viability (data not shown). While 
CCL5 was the other chemokine significantly upregulated in the skin of allo-WT mice 
(Figure 5.2), we saw no CCL5 production from mast cells in this context, though previous 
papers from our group have pointed out donor-derived T-cells as the primary producers of 
CCL5 in the post-transplant setting68.  
5.3 Discussion  
As has been extensively reported by our group and others, chemokine production 
and effector cell infiltration are key instigators in both acute and chronic GVHD. The 
relative contributions of these processes may vary depending on disease status, tissue type, 
time post-transplant, and many other factors. Ultimately, it is nonetheless clear that 
recruitment of alloreactive cells to the tissues is a major initiating factor in GVHD 
pathogenesis. 
In our murine model, we see several of these phenomena recapitulated, which lends 
further credence to its effectiveness as a model of sclerodermatous chronic GVHD. As we 
discussed in Chapter 4, key characteristics of dermal cGVHD are present, including skin 
thickening due to excessive collagen deposition. Additionally, genetic markers of fibrosis 
77 
 
are upregulated, and we see that mast cells display an activated phenotype. We also show 
that activated mast cells are capable of inducing fibroblast proliferation, allowing for one 
plausible mechanism for the increase in collagen deposition. 
However, beyond the physical characteristics of GVHD, we also see a genetic and 
protein signature that fits what we know of the disease. Using RNA isolated from the skin 
of mice post-transplant, we ran a NanoString Myeloid Innate Immunity panel. This profiled 
the transcript abundance of more than seven hundred genes involved in myeloid immunity. 
We then examined this dataset for broad trends using PANTHER pathway analysis. The 
only pathway that was upregulated was “Inflammation mediated by chemokine and 
cytokine signaling,” which allowed for the possibility of significant dysregulation of 
signaling pathways using these molecules. 
Indeed, once we examined this dataset more deeply, we saw a strong signature of 
chemokine production upregulated in allo-WT but not allo-MCd mice (Figure 5.1). We 
further saw that the allo-WT animals had significant increases in transcript and protein 
levels of specific chemokines (CCL2, CCL3, CCL4, and CCL5) that can recruit canonical 
cGVHD effector cells (Figure 5.2). Levels of these chemokines significantly correlated 
with our whole-animal GVHD scoring (Figure 5.3). Additionally, the skin of allo-WT mice 
had increased tissue damage and a primarily lymphocytic immune infiltrate (Figure 5.4). 
We also showed a concomitant increase in T-cell number by immunohistochemistry, 
alongside data demonstrating increased levels of genes involved in T-cell activation and 
signaling (Figure 5.5). However, despite this overactivation, the levels of many T-cell 
cytokines were shown to not significantly differ between groups in Figure 5.7. We believe 
78 
 
this is due to the relatively small difference in number of T-cells alongside the possibility 
that these cytokines are produced by other cell types, such as macrophages or mast cells.  
Importantly, all these changes were ameliorated by mast cell-deficiency. Given the 
mast cell’s well-known role as a “sentry cell120,” it seems that in the context of cGVHD 
pathogenesis they may be necessary for initial recruitment of inflammatory cells which 
then cause a feedback loop of further inflammation and immune recruitment. Additionally, 
they may have more direct effects through their impact on fibroblast proliferation. We also 
show that mast cells are capable of production of many of the chemokines that are 
upregulated in the allo-WT animals (Figure 5.8A, B, C, columns 1, 2, 6).  
Ibrutinib is a combined BTK/ITK inhibitor known to be efficacious in treatment of 
murine and human cGVHD, for which it is currently the only FDA-approved drug34,121. 
The Jak1/Jak2 inhibitor, ruxolitinib has been effective in case studies and is currently in 
Phase 2 and 3 clinical trials for use in steroid-refractory cGVHD. Additionally, its 
molecular targets are heavily involved in mediation of cytokine and chemokine 
signaling72,122,123. Mast cells express many of the signaling molecules targeted by these 
drugs, and we therefore investigated whether chemokine production would be inhibited 
when treated with ibrutinib or ruxolitinib124,125. Indeed, we found a dose-dependent 
decrease in production of CCL2, CCL3, and CCL4 when treated with ibrutinib and 
ruxolitinib (Figures 5.8, 5.9). This phenomenon was not seen in cells treated with imatinib 
or fingolimod, which is unsurprising given the lack of exogenous S1P or SCF in the assay 
(data not shown).  Given the overexpression of these same chemokines in the skin of the 
allo-WT vs. allo-MCd mice (Figure 5.2) and the reduction in skin symptomology of 
patients treated with ibrutinib and ruxolitinib122, it may be that inhibition of mast cell 
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chemokine production is a component of the mechanism by which these inhibitors are 
clinically efficacious.  
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Figure 5.1: Genes involved in chemokine signaling are increased in allo-WT mice 
Heatmap analysis showing lowered expression of chemokine signaling genes in RNA 
extracted from the skin of allo-MCd animals compared to allo-WT animals as measured 
by NanoString. Heatmaps and gene pathway annotations were generated using NanoString 
nSolver software. 
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Figure 5.2: Mast cell deficiency results in decreased transcript and protein levels of 
chemokines in the skin of mice after allogeneic transplant  
A: Transcript as measured by NanoString, and B: protein levels of chemokines are 
upregulated in the skin of allo-WT mice, while syngeneic mice and allo-MCd mice are not 
significantly different.  (syngeneic n=6, allo-WT n=6, and allo-MCd n=8, data are 
combined from two independent transplants). Protein levels were measured by 
LEGENDplex Chemokine Cytometric Bead Array kit. All NanoString data displayed is 
from syngeneic (n=3), allo-WT (n=3), and allo-MCd (n=5) mice. P value 0.01 to 0.05 = *, 
P value 0.001 to 0.01 = **. 
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Figure 5.3: Chemokine levels correlate with overall GVHD scoring 
Protein levels of CCL2, CCL3, CCL4, and CCL5 all significantly correlate with whole-
animal GVHD scoring. R squared and P values were determined by Spearman 
nonparametric correlation. P value 0.01 to 0.05 = *. 
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Figure 5.4: Immune infiltration to the skin is ameliorated by mast cell deficiency 
A: Representative images from H+E staining show an increased immune infiltrate and 
tissue damage in skin from allo-WT animals, while syngeneic and allo-MCd animals have 
a similar phenotype. In allo-WT animals, epidermal dysregulation and an obvious dermal 
immune infiltrate is visible. B: Quantification of immune infiltrates in the skin. P value 
0.001 to 0.01 = **. 
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Figure 5.5: Immune infiltrate to the skin is primarily lymphocytic 
The immune infiltrate to the skin after allogeneic transplant was characterized by a blinded, 
board-certified pathologist as to its hematopoietic lineage and was found to be 
predominantly lymphocytic in all three groups. 
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Figure 5.6: T-cell counts and genes related to T-cell activation are significantly increased 
in WT but not MC-deficient animals after allogeneic transplant 
A: Immunohistochemistry against CD3 demonstrates a significant increase in T-
cell infiltration in the skin of allo-WT as compared to allo-MCd animals. Slides were 
digitally scanned using the Aperio ScanScope XT, then quantified for DAB chromogen 
staining across the whole tissue using the Positive Pixel Count V9 algorithm. B: Heatmap 
and gene-level analysis demonstrates significant increases in genes involved in the T-cell 
activation pathway in allo-WT as compared to allo-MCd animals as measured by 
A 
B 
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NanoString. This indicates that despite a slight but significant increase in T-cells, activation 
status of those cells widely differs between groups. Heatmaps and gene pathway 
annotations were generated using NanoString nSolver software. NanoString data displayed 
is from syngeneic (n=3), allo-WT (n=3), and allo-MCd (n=5) mice. P value 0.01 to 0.05 = 
*, P value 0.001 to 0.01 = **, P value 0.0001 to 0.001 = ***, P value <0.0001 = ****. 
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Figure 5.7: Cytokine levels in the skin are expressed at low levels but reveal mixed 
Th1/Th2 responses 
Protein levels of cytokines characteristic of Th1 and Th2 responses were measured in the 
skin. All cytokines were expressed at low levels. IL-6 and TNF-alpha were not significantly 
different between groups, but IL-4 (a Th2 cytokine) and IFN-gamma (a Th1 cytokine) were 
upregulated in WT but not MC-deficient mice after allogeneic transplant, indicative of a 
mixed response. P value 0.001 to 0.01 = **,  NS = not significant.   
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Figure 5.8: Mast cells produce chemokines upon stimulation, production of which is 
blocked by ibrutinib, a drug used in treatment of cGVHD 
Mast cells produce high levels of A: CCL2, B: CCL3, and C: CCL4 upon 
stimulation with IgE + antigen or IgE + antigen + IL-33 (column 1 vs. columns 2 and 6). 
Production of these chemokines is inhibited by treatment with ibrutinib in a dose-
dependent manner. Results shown are representative of 2-4 independent assays. Error bars 
are the SD of technical replicates. Chemokine assays were performed using the 
LEGENDplex Inflammatory Chemokine Assay kit, which measures levels of 13 
chemokines. Mast cells did not produce significant amounts of CCL5, CCL11, CCL17, 
A 
B 
C 
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CXCL1, CXCL9, CXCL10, CXCL13, CXCL5, or CCL22 (data not shown). P value 0.01 
to 0.05 = *, P value 0.0001 to 0.001 = ***, P value <0.0001 = ****. 
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Figure 5.9: Ruxolitinib also blocks mast cell chemokine production 
Mast cells produce high levels of A: CCL2, B: CCL3, and C: CCL4 upon 
stimulation with IgE + antigen or IgE + antigen + IL-33 (column 1 vs. columns 2 and 6). 
Production of these chemokines is inhibited by treatment with ibrutinib in a dose-
dependent manner. Results shown are representative of 2-4 independent assays. Error bars 
are the SD of technical replicates. Chemokine assays were performed using the 
LEGENDplex Inflammatory Chemokine Assay kit, which measures levels of 13 
chemokines. Mast cells did not produce significant amounts of CCL5, CCL11, CCL17, 
A 
B 
C 
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CXCL1, CXCL9, CXCL10, CXCL13, CXCL5, or CCL22 (data not shown). P value 0.01 
to 0.05 = *, P value 0.001 to 0.01 = **, P value 0.0001 to 0.001 = ***, P value <0.0001 = 
****, NS = not significant.  
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CHAPTER 6. MAST CELL ORIGIN AND ACTIVATION IN THE POST-
TRANSPLANT ENVIRONMENT 
6.1 Introduction 
Our data thus far has demonstrated that mast cells are strongly conditioning-
resistant cells that may be capable of surviving in the post-transplant environment. 
Additionally, we have seen in our murine model that genetic deletion of mast cells in the 
allo-MCd group significantly reduces skin manifestations of dermal cGVHD, including 
collagen deposition, inflammation, chemokine production, and immune cell infiltration. 
However, while mast cell deficiency provides a plausible mechanism, we recognize that 
these symptoms could be secondary effects. 
When pondering the role of mast cells in initiating these processes, several 
questions immediately arise. Primarily, do mast cells survive conditioning and the post-
transplant environment in vivo? Can mast cell deficient mice, when transplanted with WT 
bone marrow, have mast cells reconstitute to the tissues, and what is the time scale of this 
process? Would chemotherapy vs. TBI-based conditioning differentially affect the 
recipient mast cell populations? And lastly, when recipient-derived mast cells are 
eliminated, is that through conditioning or elimination by alloreactive donor cells? 
Some of this can be answered through the literature. Mast cells are known to be 
long-lived, surviving months or even years once mature126, so it is very possible that they 
play a role in the relatively late onset of cGVHD. Henry Claman’s work on this topic in 
the 1980’s showed that mast cells do not disappear but are activated and degranulated 
during GVHD onset64,97. Adding to this, in a recent study, Ustun et al. reported that patients 
with increased severity of gut aGVHD had fewer tissue-resident mast cells127. This implies 
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that these mast cells may be recipient-derived, having survived conditioning, and are 
subsequently eliminated by the increased influx of alloreactive cells during severe aGVHD. 
It is also known that mast cells are capable of reconstituting to the tissues of genetically 
mast cell-deficient mice when these mice are engrafted with WT marrow or mature mast 
cells, although this process took at least 12 weeks106.  
Based on this evidence, we examined our LP/J  C57BL/6 murine model of 
sclerodermatous cGVHD. If there was complete elimination of mast cells through 
conditioning and masts cell had not regenerated from wildtype bone marrow, neither our 
syngeneic, allo-WT, or allo-MCd groups would still have mast cells. Conversely, if mast 
cells survive conditioning but are eliminated quickly by alloreactive cells and are 
regenerated from wildtype bone marrow, then we would see mast cells only in the 
syngeneic group. Lastly, if recipient mast cells survive conditioning and alloreactive cell 
elimination, but mast cells do not reconstitute from the marrow, we would see them in 
syngeneic and allo-WT, but not our allo-MCd groups. 
While this experiment can hint at mast cell survival after transplant, it is not 
designed solely to answer this question and therefore our conclusions would lack rigor, in 
addition to only lasting 7 weeks. Therefore, we designed a syngeneic transplant wherein 
we would engraft HSCs from MC-deficient mice into a WT recipient. In this model, no 
mast cells will ever reconstitute from the marrow, and any mast cells present can 
definitively be shown to be recipient derived. For this experiment, we planned 3 time 
points, 60, 90, and 120 days.  
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6.2 Results 
6.2.1 Recipient mast cells in WT animals may survive conditioning and proliferate after 
allogeneic transplant 
During a bone marrow transplant, the donor stem cells reconstitute and fill the role 
previously played by the recipient bone marrow. Among these roles are hematopoiesis of 
lymphoid and myeloid immune subsets, mast cells included128. Ex vivo, we have shown 
that mast cells can survive radiation and chemotherapy, but we wanted to determine if mast 
cells were still present post-transplant in vivo; in addition to radiation, recipient-derived 
mast cells could also be eliminated by alloreactive donor T-cells. Therefore, we used 
histochemical and fluorescent methods to examine tissue sites where mast cells are tropic, 
including skin, ear, and trachea, as well as other GVHD target organs (small intestine, lung 
and liver).  
In the first set of experiments, seven weeks after transplant, organ tissue was stained 
with toluidine blue and mast cells were counted per high-power field (400x). Skin, ear, and 
tracheal tissue showed a similar pattern, with low numbers of mast cells in syngeneic 
animals, higher numbers in allo-WT animals, and low-to-undetectable levels of mast cells 
in allo-MCd animals (Figures 6.1, 6.2). To confirm the identity of the toluidine blue-
positive cells, we stained skin slides with avidin conjugated to the Texas Red fluorophore 
and counted the number of stained cells per high-power field. Avidin has been shown to 
stain mast cells in a biotin-independent manner129,130 and skin/ear sections from each 
animal showed similar numbers and distribution in the tissue (Figure 6.3). In small 
intestine, lung, and liver, mast cell numbers were low-to-undetectable and there were no 
differences between groups (data not shown). Findings were verified by a blinded, 
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independent researcher. To confirm our finding in the skin, we returned to our NanoString 
data set, where we found that mast cell-specific genes including chymase, tryptase, 
FCeR1a, and Cpa3 were expressed at extremely low levels in the skin of allo-MCd mice 
(Figure 6.4). 
6.2.2 Recipient mast cells are not eliminated by chemotherapy or irradiation-based 
conditioning and are maintained after syngeneic transplant 
We next performed a syngeneic transplant designed to identify recipient-derived 
mast cells that survive conditioning by either chemotherapy or TBI. The transplant layout 
is shown in Figure 6.5. At 60, 90, and 120 days, we sacrificed mice and took skin and ear 
biopsies to examine mast cell numbers. When stained with avidin, we saw that there were 
minor reductions in mast cell counts in both skin and ear when transplanted using either 
chemotherapy or TBI-based conditioning. However, we saw that mast cells ultimately 
survived over a long period of time, as mast cell numbers in the tissues were maintained at 
approximately fifty percent or more of the values seen at day 60, even out to 120 days 
(Figure 6.6).  
We confirmed this finding with toluidine blue staining of skin and ear sections, 
which not only showed the same trend and similar values (Figure 6.7A), but a significant 
correlation between avidin- and toluidine blue-positive cells (Figure 6.7B).  Representative 
images of toluidine blue-stained skin and ear tissue from mice sacrificed at day 120 clearly 
show the presence of mast cells even at this late timepoint post-transplant (Figure 6.8). 
Taken together, these data definitively show that mast cells are capable of surviving 
conditioning and the post-transplant environment, though future studies will need to 
confirm these findings in the setting of an allogeneic transplant.  
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6.3 Discussion  
In this allogeneic LP/J  C57BL/6 transplant, our data has clearly demonstrated 
that mast cell-deficiency was maintained in the allo-MCd group, while the syngeneic and 
allo-WT groups still had significant numbers of mast cells, as measured by toluidine blue 
and avidin staining (Figure 6.1-6.3). This finding was confirmed by transcript-level 
analysis of mast cell-specific genes (Figure 6.4). The extremely low numbers of mast cells 
in the allo-MCd compared to our allo-WT and syngeneic groups, even 7 weeks post-
transplant, imply that mast cells were unable to fully reconstitute from the bone marrow 
into their tissue niche. Given that mast cells are known to be capable of reconstitution to 
skin and ear within 12 weeks post-bone marrow transplant106,  we believe that the mast 
cells in the allo-WT and syngeneic groups may be recipient-derived. However, our model 
did not allow for definitive recipient vs. donor differentiation and there may be other factors 
driving this disparity in mast cell numbers. 
Therefore, we performed a syngeneic transplant designed to definitively determine 
whether recipient-derived cells could survive conditioning, and for what length of time 
they would survive post-transplant (Figure 6.5). At 60 days, mast cells were still present, 
as determined by both avidin and toluidine blue staining. When we examined the 90 and 
120-day timepoints, we saw that while there were mild reductions in mast cell numbers in 
the tissue, we could definitively show that many mast cells survive even 120 days after 
transplant (Figure 6.6-6.7, representative images in Figure 6.8). This data shows that mast 
cells do indeed survive after transplant and could therefore be capable of inducing many of 
the pathologies seen in Chapter 4. Expanding a similar set of experiments into allogeneic 
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transplant will allow us to determine the degree of alloreactive elimination of mast cells 
that may be taking place in the post-transplant environment.    
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Figure 6.1: Toluidine blue staining reveals increased levels of mast cells in the skin of 
WT recipients and no reconstitution of mast cells in the allo-MCd group after allogeneic 
bone marrow transplant. 
Mast cell counts and toluidine blue-stained representative images in the skin of syngeneic 
(n=6), allo-WT (n=16), and allo-MCd (n=14) animals. Mast cell counts per high-power 
field (400x) are displayed alongside images from animals whose mast cell count was 
nearest the mean value for the group. Mast cells (arrows) were denoted by metachromatic 
staining and granular appearance. At 7 weeks post-transplant, mast cells had not 
reconstituted from the LP/J marrow, implying that recipient mast cells may have survived 
conditioning. P value 0.01 to 0.05 = *, P value <0.0001 = ****. 
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Figure 6.2: Mast cell deficiency was maintained in the allo-MCd group in other tissues 
Mast cell counts and toluidine blue-stained representative images in the skin of syngeneic 
(n=6), allo-WT (n=16), and allo-MCd (n=14) animals. Mast cell counts per high-power 
field (400x) are displayed alongside images from animals whose mast cell count was 
nearest the mean value for the group. Mast cells (arrows) were denoted by metachromatic 
staining and granular appearance. Ear and trachea are two tissues where mast cells are 
normally present, and the trends visible in Figure 6.1 hold true; mast cells are increased in 
WT recipients but have not reconstituted from the marrow in the allo-MCd group. P value 
0.01 to 0.05 = *, P value 0.001 to 0.01 = **, P value <0.0001 = ****.   
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Figure 6.3: Avidin staining of mast cell granules confirms our toluidine blue findings 
Avidin conjugated to the Texas Red fluorophore specifically binds mast cell granules. Mast 
cell counts and avidin-stained representative images in the skin of syngeneic (n=6), allo-
WT (n=16), and allo-MCd (n=14) animals. Mast cell counts per high-power field (400x) 
are displayed alongside images from animals whose mast cell count was nearest the mean 
value for the group. We confirmed our previous findings using this alternate method.  
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Figure 6.4: Mast cell-specific genes are decreased in the skin of allo-MCd mice 
Levels of mast cell-specific genes in the skin are significantly lowered in allo-MCd mice. 
Data displayed is from syngeneic (n=3), allo-WT (n=3), and allo-MCd (n=5) mice, as 
measured by NanoString analysis. P value 0.01 to 0.05 = *, P value 0.001 to 0.01 = **. 
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Figure 6.5: Layout of a transplant to determine if recipient mast cells survive 
conditioning 
We performed a syngeneic transplant using MC-deficient mice as donors. In this way, no 
mast cells will ever reconstitute from the marrow; therefore, any mast cells present in the 
tissues will be recipient-derived cells. For conditioning, we used both TBI and 
busulfan/cyclophosphamide-based chemotherapy to better recapitulate the more common 
clinical utilization. Analysis was performed at 60, 90, and 120 days post-transplant. 
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Figure 6.6: Recipient mast cells survive conditioning and the post-transplant environment  
Tissue from mice having undergone a syngeneic transplant with either chemotherapy or 
radiation-based conditioning was removed, fixed, and stained with avidin for mast cell 
granules. Mast cells were still present, although reduced, in skin and ear, even out to 120 
days post-transplant. P value 0.01 to 0.05 = *, P value 0.001 to 0.01 = **, NS = not 
significant. 
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Figure 6.7: Toluidine blue staining confirms the survival of recipient mast cells 
A: Staining with toluidine blue confirmed our findings from our avidin-stained sections. 
Recipient mast cells are present, although reduced, out to 120 days in skin and ear, across 
both chemotherapy and radiation groups. B: Additionally, toluidine blue and avidin 
staining demonstrated a high degree of correspondence between the two stains. P value 
0.01 to 0.05 = *, P value 0.001 to 0.01 = **, NS = not significant. 
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Figure 6.8: Representative images of toluidine blue staining at 120 days post-transplant 
Toluidine blue staining of 120-day skin and ear sections (400x) reveals the presence of 
mast cells in skin and ear tissue  
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CHAPTER 7. OVERALL DISCUSSION 
Hematopoietic stem cell transplant (HSCT) is a potentially curative therapy for 
many leukemias, lymphomas, metabolic disorders, or inborn defects of hematopoiesis. 
While autologous and syngeneic HSCTs allow for a minimization of disease burden prior 
to treatment, they also run the risk of increased relapse of primary disease. For this reason, 
allogeneic HSCT is often indicated where the primary disease is particularly aggressive, 
such as in acute myeloid leukemia20. In allogeneic HSCT, the alloreactive donor-derived 
immune cells recognize and destroy the residual cancer cells, an effect known as the graft-
versus-leukemia effect26.  
However, these same alloreactive donor immune cells can also respond against host 
tissues, causing both focal and diffuse damage across multiple organ systems, a 
phenomenon known as graft-versus-host disease (GVHD). GVHD can range in outcome 
from mild to lethal and it is the single largest barrier to widespread therapeutic use of allo-
HSCT. While certain immune subsets are well-understood for their role in GVHD 
pathogenesis, targeting these often involves broad-spectrum immunosuppression. This 
treatment is not always tolerable for patients, especially in the long-term, and can often 
lead to increases in primary disease relapse or potentially lethal infections42.  
The current understanding of the pathogenesis of GVHD has therefore been 
insufficient to prevent or treat GVHD in some patients, many of whom can become 
refractory to long-term steroids or suffer other debilitating side effects114. Broadly, my 
research interests upon joining the lab of Dr. Gerhard Hildebrandt were to search for factors 
that initiate and maintain GVHD that may be targetable outside the context of 
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immunosuppression. Over the course of my graduate work, these have narrowed and 
matured into the subject of this dissertation; the role of mast cells in the pathogenesis of 
chronic graft-versus-host disease.  
My interest in mast cells was initially piqued by work from Henry Claman, a 
seminal immunologist. In 1985, he described the disappearance of mast cells from Balb/C 
mice after irradiation and injection of B10.D2 marrow64. This is now established as a model 
of sclerodermatous cGVHD but had not been extensively explored at the time. Indeed, 
Claman’s use of this model was predicated on its utility as a model of progressive 
scleroderma, a phenomenon that was only poorly explicable at the time.  
While this mast cell disappearance was not unexpected given the high dose of 
irradiation (9 Gy) and the paradigm of host cell elimination during conditioning, Claman 
was nonetheless unsure of why it took place. He hypothesized that mast cells may not be 
eliminated, but rather degranulated, and therefore largely invisible to the staining methods 
of the time. In 1986, he followed up on this hypothesis, demonstrating that mast cells did 
in fact disappear from skin staining, but they were not eliminated. When examined by 
ultrastructural analysis via electron microscopy, mast cells were clearly still present, albeit 
degranulated. Claman referred to these as “phantom mast cells,” and demonstrated that 
they showed an activated phenotype and were slowly rebuilding their granule contents97.  
Looking back at these studies from the span of several decades, it is clear that there 
was more to this story than Claman initially suspected. Given many of the characteristics 
seen, I thought that these studies may hint at the possibility of some GVHD biology that 
had been understudied. The degranulation of mast cells early in the onset of GVHD 
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symptoms allows for a convenient trigger for the initial inflammatory cascade, which can 
then be further propagated in the context of the alloreactive feedback loop known to exist 
in acute GVHD. Further, the fact that skin mast cells degranulate and rebuild their granule 
contents rather than merely disappearing allows for the possibility that recipient-derived 
mast cells have survived conditioning, although these studies were too nonspecific to 
rigorously answer that question. Additionally, if these mast cells are resistant to irradiation, 
is it possible that they may also survive other forms of conditioning, such as chemotherapy-
based regimens? Lastly, given this activated mast cell phenotype alongside the clinical 
evidence of scleroderma, is it possible that mast cells are important in the progression of 
this disease? 
The number of questions raised by these studies speaks to Henry Claman’s 
propensity for addressing the fundamental biology behind the immune system. While he is 
better known for his work establishing the basis of T- and B-cell cooperation in antibody 
production, he was also an allergist and mast cells were a cell type he understood well. I 
would be remiss to continue further in this dissertation without acknowledging that his 
work truly underlies my own, and that the clarity and structure of his papers in the 1985-
1986 period allowed for more straightforward follow up studies than would have otherwise 
been possible. 
However, for several years after this work, the study of mast cells in GVHD 
pathogenesis languished. Interest was revived by Francesca Levi-Schaffer in her work with 
Henry Claman. While Claman noted the activated mast cell phenotype, Levi-Schaffer dug 
further into the mechanism. She discovered that supernatants from splenic cells isolated 
from mice with GVHD strongly activated mast cells, in contrast to supernatants from 
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healthy mice105. This demonstrates that the donor immune system is capable of producing 
factors that induce mast cell activation. She also showed that mast cell co-culture with 
fibroblasts isolated from mice with GVHD induced mast cell proliferation78, although both 
of these studies were entirely in vitro. 
Since Dr. Levi-Schaffer’s work in the early 1990’s, there had been few notable  
studies on the topic until 2013, when Leveson-Gower and Robert Negrin published on an 
immunomodulatory role for mast cells during the onset of acute GVHD. They used a fully 
MHC-mismatched model of GVHD and showed that the absence of mast cells led to 
significant increases in GVHD severity compared to WT mice66. However, this 
phenomenon was at least partially dependent on IL-10 production by mast cells. 
While at first glance, this immunomodulatory role seems contradictory to previous 
experiments, it is in fact of great interest. Mast cells are a cell type heavily involved in 
allergy, which is notoriously skewed towards Type 2 or Th2 immunity99. Therefore, mast 
cell production of IL-10, a Th2 cytokine, fits with their previously understood role. 
Additionally, while aGVHD is known for its inflammatory (Type 1) nature, cGVHD tends 
to be much more dominated by Type 2 responses. Therefore, an immunomodulatory mast 
cell, while initially helpful in the burst of inflammation accompanying aGVHD onset, may 
continue to act in a Type 2 manner; aberrant and prolonged Type 2 responses are known 
to result in pathogenic fibrosis similar to that seen in cGVHD85. 
All of this prior work led us to examine mast cells in the context of chronic GVHD 
using more modern methods. In the course of planning for these experiments, we came to 
wonder whether it would be best to examine the impact of mast cells derived from donor 
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or from recipient. We therefore established an ex vivo system (Figure 3.1) wherein we 
could test mast cell survival after exposure to various agents used in pre-transplant 
conditioning. If the mast cells immediately died after exposure, it would lend credence to 
the theory that donor-derived mast cells reconstituted quickly from the bone marrow. 
However, if mast cells survived this challenge, it would imply that they may be capable of 
surviving conditioning, and that recipient-derived mast cells may still be capable of 
exerting their effects on the surrounding tissue during GVHD onset.  
When we exposed mast cells to the same radiation source and dose (Cesium, 8.5Gy) 
used in conditioning for the LP/J  C567BL/6 model, we saw that they had no change in 
cellular number or viability after 96 hours. Indeed, even at 20Gy, a supralethal dose initially 
intended as a positive control for cell death, mast cells continued to have no reduction in 
cell count or viability (Figure 3.2). However, 96 hours after exposure does not capture the 
time frame usually seen in aGVHD onset (approximately 7 days) and this experiment did 
not take into account one of the most common myeloablative conditioning regimens in 
clinical use, busulfan/cyclophosphamide (Bu/Cy). Therefore, we repeated this assay with 
exposure to both TBI and Bu/Cy and measured out to 10 days. Again, we saw no decrease 
in cell count or viability. Indeed, mast cell number actually increased relative to day 0 of 
treatment across all groups, possibly indicative of cell proliferation (Figure 3.3).  
However, this assay merely tells us that mast cells may survive conditioning; it 
answers nothing about mast cell functionality. Since the majority of murine GVHD models 
use TBI for conditioning, we examined mast cell expression of CD107a, a marker of 
cellular degranulation, after exposure to 8.5 and 20Gy of radiation. We saw that at both 
doses, mast cells were still capable of degranulation at levels no different than unirradiated 
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controls (Figure 3.4). This implies that mast cells may survive conditioning and retain one 
of their primary functions, cellular degranulation, lending credence to the idea that 
recipient-derived mast cells could be present and active during onset of cGVHD.   
To move this study in vivo, we began by examining what models would be available 
to us. The lab of Steve Galli, a world leader in the biology of mast cells, had deposited at 
Jackson Labs a strain of mast cell-deficient mice derived from the C57BL/6 mouse106. 
While C57BL/6 are used for many models of aGVHD, there is only one model of cGVHD 
which would allow us to use these mice. The LP/J  C57BL/6 model of cGVHD is, 
serendipitously, a model characterized by progressive and systemic dermal sclerosis53; we 
have already seen evidence that mast cells may be involved in such processes. Based on 
previous work and our preliminary data demonstrating mast cell survival, we opted to 
examine the role of recipient-mast cells in cGVHD onset.  
To better fit into the previous literature, this transplant solely used 8.5Gy TBI for 
conditioning, as had been previously reported34. As shown in Figure 4.1, there would be 
three groups: a C57BL/6  C57BL/6 syngeneic transplant which would serve as a negative 
control for disease progression, a LP/J  C57BL/6 allogeneic transplant (allo-WT), and a 
LP/J  C57BL/6 MC-deficient animals, our experimental group (allo-MCd).  Mice would 
be analyzed upon either reaching morbidity due to cGVHD or after 7 weeks.  
After this transplant was performed, a striking clinical phenotype became apparent, 
as the allo-MCd group was developing significantly less cGVHD symptomology. 3 mice 
in the allo-WT group had to be euthanized due to morbidity, while none developed severe 
disease in the allo-MCd animals (Figure 4.2A). Further, a whole-animal GVHD scoring 
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system showed a large reduction in overall scoring after transplant in the allo-MCd animals 
(Figure 4.2B). After the 7-week timepoint, tissues from the mice were scored by a blinded 
pathologist and it was found that only the skin of allo-WT animals developed significant 
GVHD characteristics, while allo-MCd and syngeneic animals were not significantly 
different. 
A classical feature of dermal cGVHD is skin thickening, especially due to 
significant collagen deposition in the dermal layer. We therefore examined the dermis of 
these mice by Masson’s trichrome staining which stains collagen a deep blue. A thin, 
diffuse, and well-ordered layer of collagen was visible in the syngeneic and allo-MCd 
animals, while the allo-WT animals had a much thicker and denser layer of collagen 
(Figure 4.4).  
 Taken together, these symptoms demonstrate several things: first, we were able to 
recapitulate the sclerodermatous cGVHD symptomology (whole animal disease, skin 
thickening and lesioning) for which the LP/J  C57BL/6 model is known. Second, these 
symptoms were significantly ameliorated in the allo-MCd animals. While our hypothesis 
anticipated this, the difference between allogeneic groups was nonetheless striking, 
especially as cGVHD is considered to be so multifactorial. Lastly, it became increasingly 
clear that while mast cells may be critical in initiating cGVHD, at least in this model 
system, we would need to establish a mechanism by which this took place. While mast 
cells had not previously been implicated in cGVHD pathogenesis, a known mechanism 
would allow us to examine the presence or absence of possible mast cell contribution in 
disparate murine and human models.  
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 To that end, we took a broader approach to our analysis. Nanostring analysis on the 
skin of mice across all three groups demonstrated striking differences in genes associated 
with fibrosis (Figure 4.5). Mast cells were also activated in the allo-WT animals (Figure 
4.6). The juxtaposition of these two factors led us to wonder whether mast cells could have 
a direct effect on dermal fibroblast populations. When we cultured murine skin-derived 
fibroblasts with supernatants from quiescent or activated mast cells, the supernatants from 
activated cells significantly increased fibroblast proliferation (Figure 4.7). As has been 
mentioned, Levi-Schaffer had previously reported that cGVHD fibroblasts could stimulate 
mast cell proliferation; now we see the corollary. This evidences a possible mast 
cell/fibroblast feedback loop in cGVHD. Because of this, in patients with dermal cGVHD, 
I would expect to see mast cell infiltrates alongside significant collagen deposition, even 
as many other inflammatory cells may be sparse.  
 We therefore examined skin biopsies from patients with dermal cGVHD who had 
undergone transplant at the UK Markey Cancer Center. They displayed characteristic 
features of cGVHD, including skin thickening and a scattered and diffuse immune cell 
infiltrate when examined by H+E staining. When stained for tryptase, a mast cell marker, 
patients with cGVHD had a significant increase in dermal mast cells as compared to 
healthy controls (Figure 4.8). Of course, while any retrospective clinical study is correlative 
in nature, this does lend credence to mast cells being involved in human, as well as murine, 
cGVHD. 
 Both acute and chronic GVHD are, at some level, initiated or maintained through 
infiltration of immune cells and inflammation. This immune infiltration can often be 
secondary to dysregulated cytokine and chemokine signaling in the tissues that  leads to 
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recruitment of these inflammatory cells, which subsequently become activated and cause 
the tissue damage seen in GVHD. In particular, CCL5 is known to be critical in aGVHD68, 
while CXCL10 is the most consistent biomarker seen in cGVHD studies35.  
 However, it is largely unknown as to which cell type produces the chemokines 
involved in this inflammatory cascade. While some specific examples have been 
discovered, such as the role of donor-derived T-cells in CCL5 production68, oftentimes it 
is assumed to be tissue resident cells, such as macrophages, that produce these factors. 
However, there is substantial evidence that both human and murine mast cells may be 
capable of producing a huge variety of chemokines and cytokines, depending on the 
stimulus, in order to fine-tune the type and degree of inflammatory infiltrate75,131. 
Therefore, we hypothesized that mast cells may be one of the primary producers of 
chemokines in the post-transplant environment. Reductions in chemokine levels in the allo-
MCd mice would allow us to see both primary production of chemokines by mast cells, as 
well as the secondary effects that a lack of mast cells has on the tissue microenvironment. 
 Therefore, we reexamined our NanoString data to look for broad trends in the data. 
We performed PANTHER pathway analysis to examine the skin for types of cellular 
processes that may be upregulated. When we analyzed the sets of genes that were 
differentially expressed between allo-MCd and allo-WT skin, only one pathway was 
significantly different; inflammation mediated by chemokine and cytokine signaling. A 
heatmap of the genes involved in chemokine signaling pathways is shown in Figure 5.1. 
As you can see, the allo-WT group had significant upregulation of these pathways, while 
the syngeneic and allo-MCd groups did not. Additionally, when we examined several of 
the most differentially expressed genes in this pathway, we saw genes coding for CCL2, 
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CCL3, CCL4, and CCL5 were all significantly higher in allo-WT animals than other groups 
(Figure 5.2A). Since transcript-level analysis does not always track with protein 
expression, we also measured protein levels of these chemokines, finding the exact same 
trend as with transcript (Figure 5.2B). 
 Chemokine expression in this context is not necessarily meaningful unless it 
correlates with clinical outcome. Therefore, we analyzed expression levels of each of these 
chemokines alongside the GVHD score of individual mice and saw that there was excellent 
correlation between the two (Figure 5.3). While correlation does not imply causation, it is 
nonetheless interesting that all levels of all 4 chemokines tracked so well with whole-
animal GVHD scoring. There was also an evident increase in dermal immune infiltrate in 
allo-WT animals (Figure 5.4) which was primarily lymphocytic in nature (Figure 5.5). 
Indeed, T-cells and markers of T-cell activation were also significantly higher in allo-WT 
animals (Figure 5.6). Importantly, all of these changes were ameliorated in the allo-MCd 
animals, indicating that mast cell responses are critical for GVHD.  
 However, despite these changes, we do not know whether mast cells are directly or 
indirectly responsible. Given the mast cell-dependent nature of chemokine upregulation in 
the skin, we decided to examine mast cells ex vivo for their capacity to produce these 
chemokines. Additionally, we also drugged mast cells with compounds used clinically in 
the treatment of steroid-refractory cGVHD, ibrutinib and ruxolitinib. Mast cells produced 
high levels of CCL2, CCL3, and CCL4 upon activation with IgE with or without IL-33, 
production of which was blocked in a dose-dependent manner by either ibrutinib or 
ruxolitinib (Figures 5.8, 5.9). 
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 What these data show, particularly in the allo-WT mice, is a classic example of 
cGVHD symptomology. After BMT, the mice in this model are known to develop 
scleroderma, and a chemokine-driven diffuse inflammatory cell infiltrate. The novelty is 
in the addition of the allo-MCd group, which as we showed, does not develop many of the 
same characteristics. Not only do the animals get less sick and fewer dermal manifestations, 
but chemokine production is significantly and specifically decreased. Additionally, 
immune infiltrate is not significantly different than in a syngeneic transplant. What we can 
take away from this experiment is a confidence that mast cells are crucial mediators for 
fibrosis and effector cell recruitment in this context.  
 Additionally, this allows us some insight into mechanisms by which GVHD could 
be further lessened. Ibrutinib is FDA-approved for treatment of steroid-refractory 
cGVHD121, and ruxolitinib has recently finished its Phase 3 trial for the same indication, 
meeting both primary and secondary endpoints72. These drugs are potentially game-
changing in treatment and management of cGVHD. Our data demonstrating that mast cells 
produce many of the same chemokines seen to be significantly upregulated after allogeneic 
transplant allows for modulation of mast cell activity. Mast cells use the ibrutinib and 
ruxolitinib target proteins (BTK/ITK and Jak1/Jak2, respectively) as key mediators in 
cytokine signal transduction and downstream of FCeR1a.Therefore, while these studies did 
not address the mechanism by which mast cells are being activated in cGVHD, these drugs 
block many of the key signaling pathways.  
Indeed, several studies have shown that mast cells are amenable to inhibition with 
these molecules in other contexts132–134. There is no reason to believe that mast cell 
activation in the context of cGVHD would not be similarly inhibited by these compounds. 
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Given that we see a dose-dependent reduction in chemokine signaling with both ibrutinib 
and ruxolitinib, we propose that their inhibition of mast cell activation and chemokine 
production may be key mechanisms by which these drugs are clinically efficacious.  
 While we have shown that cGVHD development in this model is mast cell-
dependent, we have not addressed one of our initial questions; are these mast cells derived 
from donor or recipient? Even if there was a theoretically perfect drug to inhibit mast cell 
activity, the kinetics of dosing would be dependent on the mast cell origin. Leveson-Gower 
showed that mast cells can be beneficial in some contexts, and so complete inhibition 
would likely be detrimental.  
 We therefore stained for mast cells in the tissues after transplant. It was 
immediately clear that mast cells were still present in the syngeneic and allo-WT groups, 
but that the allo-MCd animals remained almost entirely mast cell-deficient across multiple 
tissues (Figure 6.1, 6.2). To confirm this striking observation, we stained with avidin, 
which selectively binds to mast cell granules. Again, we saw that no mast cells were present 
in the allo-MCd animals (Figure 6.3). Additionally, levels of mast cell-specific genes in 
the skin were extremely low (Figure 6.4). What this tells us is that in this transplant, the 
mast cells in the syngeneic and allo-WT groups were likely recipient-derived. If donor mast 
cells had reconstituted from the marrow, we would have also seen the presence of mast 
cells in the allo-MCd animals; while they are genetically incapable of producing mast cells, 
they are perfectly capable of supporting mast cell growth and survival if they are engrafted 
into the mouse106.  
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However, while this is logical, it is insufficiently rigorous to completely answer the 
question of donor-vs.-recipient origin. Therefore, we designed a separate transplant in 
which marrow and splenocytes from MCd mice would be injected into WT C57BL/6 mice 
after either TBI or chemotherapy-based conditioning (Figure 6.5). In this way, since the 
marrow would be incapable of producing new mast cells, any mast cells in the tissues must 
be recipient-derived, having survived conditioning and the post-transplant environment.  
After transplanting the mice, analysis was performed 60, 90, and 120 days later. 
When stained with avidin (Figure 6.6) or toluidine blue (Figure 6.7A), mast cells were 
slightly reduced, though still present after 60, 90, or 120 days in groups that had undergone 
either chemotherapeutic or TBI-based conditioning. Confirming that both mast cell stains 
worked well and were staining the same cells, we examined each mouse for correlation 
between the two methods (Figure 6.7B). Representative images of mice at day 120 are 
shown in Figure 6.8 and show that mast cells were still present at this timepoint. 
This is the first direct evidence of recipient-derived mast cell survival after 
transplant. Mast cell survival out to 120 days was surprising and remarkable; even as it is 
known that mast cells are long-lived. For many mice, 120 days may be a significant portion 
of the total lifespan of the organism, adding further credence to the “long-lived” mast cell 
moniker.  
However, there is much work left to do and many questions still to ask in this field. 
To begin with, I would like to address some potential shortcomings or issues with our 
approach in these studies. The B6.Cg-KitW-sh/HNihrJaeBsmGlliJ mast cell-deficient mice 
ae well characterized and have been used to model the role of mast cells across many 
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diseases. However, strictly isolating the role of mast cells using this model can be 
problematic due to the nature of the genetic changes in this model that allow for mast cell-
deficiency. Most murine models of mast cell-deficiency are based around disruptions of 
the Kit gene, but this particular model has a genetic inversion covering several dozen genes, 
including some that are involved in immune function135,136. This can therefore lead to a 
false signal if one of the other genes is critical for disease processes independent of mast 
cells137.  
This raises another point; while we have amassed a significant amount of data on 
the effects of mast cell-deficiency in GVHD, much of it could be attributed to secondary 
effects. This could be, as mentioned, due to genetic factors involved in the Kit inversion. 
Another possibility is that while mast cells seem to be involved in creating a pro-
inflammatory environment early on in the disease pathogenesis, they may be less critical 
once an inflammatory infiltrate is established. Therefore, once present in the tissues, more 
canonical GVHD effector cells such as neutrophils or T-cells may be capable of driving 
the disease even in the absence of mast cells.  
These pitfalls are important for the future research direction of our lab, and more 
broadly, the GVHD field. To begin with, addressing the issue of the Kit inversion is 
relatively straightforward. Several labs have developed murine models of Kit-independent 
mast cell-deficiency across multiple genetic backgrounds138–140. These include both 
constitutive and inducible mast cell knockouts, most commonly involving the Cpa3 gene 
which is critical for mast cell development and function. While not received in time to use 
in my studies, the lab of Hans Reimer-Rodewald has a Cpa3 model of mast cell-deficiency 
on the Balb/C background138, which would allow us to use a second model of 
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sclerodermatous cGVHD, the B10.D2  Balb/C model. Other mouse models have 
genetically encoded tagging proteins under the Cpa3 mast cell promoter, allowing for easy 
identification, tagging, or removal of mast cells from the tissues in order for single cell 
analysis. Studies using these models would add significant rigor and specificity to our 
current data.  
Another area of interest for future studies would be to determine the mechanism of 
activation of mast cells in the post-transplant environment. As has been discussed, the main 
methods of mast cell activation are via IgE or IL-33 signaling. Therefore, we plan to use 
transgenic mouse models of FCeR1a, IL-33, or ST2 (the IL-33 receptor) deficiency which 
will be provided to us by our collaborators at the University of Pittsburgh. When used in 
the LP/J  C57BL/6 model of cGVHD, we will be able to determine whether mast cell 
activation is regulated by either or both of these molecules. This could allow for more 
precise targeting of mast cell function, especially in conjunction with pharmaceutical 
intervention.  
Indeed, while therapeutic targeting of mast cells is difficult due to the non-
specificity of most drugs that affect mast cell responses (such as cromolyn sodium, 
ibrutinib, and ruxolitinib), we are developing mechanisms by which individual mast cells 
can be isolated after treatment in order to determine their phenotype. We are also in talks 
with a pharmaceutical company to initiate a Phase I clinical trial to examine a proprietary 
mast cell inhibitor in the context of cGVHD. These studies will allow us to determine 
mechanisms of mast cell activation and possible therapeutic interventions by which they 
may be targeted for the treatment or prevention of cGVHD. This is demonstrated in Figure 
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7.1, where we show the mechanisms by which mast cells induce cGVHD in our model, as 
well as possible pathways that could be targeted for therapeutic intervention. 
Lastly, we have a study in progress aiming to determine the donor-vs.-recipient 
origin of mast cells in the context of an allogeneic transplant. This utilizes mice with 
CD45.1+ recipients vs. CD45.2 donors. Therefore, this will allow us to determine immune 
chimerism, as well as the kinetics of tissue mast cell replacement from the marrow. This 
will allow for significant insight into the dynamics of mast cell activation, killing by 
alloreactive cells, and replacement from the marrow in the post-allogeneic transplant 
environment. 
Ultimately, these studies are only a beginning. While we show that many of the 
features of murine chronic GVHD are dependent on mast cells, this work raises many 
questions in regard to their mechanism of activation, their survival after allogeneic 
transplant, and their normal physiological roles. While the mast cell, particularly in the 
context of allergy, is viewed as relatively one-dimensional, these studies put the lie to that 
paradigm.  
In summary, this dissertation shows that mast cells are viable and capable of 
maintaining their functional capabilities after irradiation. Chemotherapeutic regimens 
similar to those used in pre-transplant conditioning also had no effect on cell count or 
viability. We show that in vivo, cGVHD-related complications of allogeneic transplant, 
including skin fibrosis and effector cell recruitment, are minimized in MC-deficient mice, 
and that human patients with dermal cGVHD have increased mast cell numbers in the skin. 
We show that mast cells are regulated by drugs currently used in treatment of cGVHD, and 
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that in vivo, recipient-derived mast cells are not eliminated by conditioning or the post-
transplant environment. Lastly, we establish a framework of future experiments which 
could lead to more specific and targetable therapeutic intervention for mast cells in 
cGVHD.  
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Figure 7.1: Targetable pathways of mast cell-mediated propagation of cGVHD 
We have shown that mast cells are involved in the propagation of dermal cGVHD. These 
mast cells survive conditioning and induce cGVHD symptomology through their 
interactions with fibroblasts and their recruitment of alloreactive immune effector cells. 
We here show these pathways and means by which they may be therapeutically targeted. 
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LIST OF ABBREVIATIONS 
AEU  Allergic Effector Unit 
aGVHD  Acute Graft-versus-Host Disease 
Allo-HSCT  Allogeneic Hematopoietic Stem Cell Transplant 
Allo-MCd  Allogeneic - Mast Cell-Deficient 
Allo-WT  Allogeneic - Wild Type 
AML  Acute Myeloid Leukemia 
APC  Antigen Presenting Cell 
ATP  Adenosine Triphosphate 
BD  Becton-Dickinson 
bFGF  Basic Fibroblast Growth Factor 
BM  Bone Marrow 
BOS  Bronchiolitis Obliterans Syndrome 
BPTP SRF  Biospecimen Procurement and Translational Pathology Shared Resource Facility 
BTK  Bruton's Tyrosine Kinase 
Bu-Cy  Busulfan/Cyclophosphamide 
CD  Cluster of Differentiation 
cGVHD  Chronic Graft-versus-Host Disease 
CML  Chronic Myeloid Leukemia 
CO2  Carbon Dioxide 
DAMP  Danger-Associated Molecular Pattern 
DCs  Dendritic Cells 
DHHS  Department of Health and Human Services 
125 
 
DMEM  Dulbecco's Modified Eagle's Medium 
DMSO  Dimethyl Sulfoxide 
DNA  Deoxyribonucleic Acid 
DNP  Dinitrophenol 
FCeR1a  FC Epsilon Receptor 1a 
FDA  Food and Drug Administration 
GC  Germinal Center 
G-CSF  Granulocyte Colony Stimulating Factor 
GI  Gastrointestinal 
GVHD  Graft-versus-Host Disease 
GVL  Graft-versus-Leukemia 
Gy  Gray (unit of radiation) 
H+E  Hematoxylin and Eosin 
HLA  Human Leukocyte Antigen 
HSCT  Hematopoietic Stem Cell Transplant 
IACUC  Institutional Animal Care and Use Committee 
IFN  Interferon 
IFN-
gamma 
 Interferon Gamma 
IgE  Immunoglobulin E 
IHC  Immunohistochemistry 
IL  Interleukin 
IRB  Institutional Review Board 
Jak  Janus Kinase 
MCd  Mast Cell-Deficient 
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MCs  Mast Cells 
MHA  Minor Histocompatibility Antigen 
MHC  Major Histocompatibility Complex 
MIMG  Microbiology, Immunology, and Molecular Genetics 
NK cell  Natural Killer Cell 
NMA  Non-myeloablative 
PAMP  Pathogen-Associated Molecular Pattern 
PANTHER  Protein Analysis Through Evolutionary Relationships 
qPCR  Quantitative Polymerase Chain Reaction 
qRT-PCR  Quantitative Reverse Transcription Polymerase Chain Reaction 
RIC  Reduced-Intensity Conditioning 
RNA  Ribonucleic Acid 
ROS  Reactive Oxygen Species 
RPMI  Roswell Park Memorial Institute Medium 
SCF  Stem Cell Factor 
TBI  Total Body Irradiation 
Tfh  T-follicular Helper 
TGF-beta  Transforming Growth Factor Beta 
Th  T-helper  
TLR  Toll-Like Receptor 
TNF-alpha  Tumor Necrosis Factor Alpha 
Treg  T-regulatory cell 
UK  University of Kentucky 
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VEGF  Vascular Endothelial Growth Factor 
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